420 result(s) found
Abdominal Aortic Aneurysm
This is a prospective, multi-center, non-randomized, single arm, post-approval study. The main objective of this study is collection of the real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of abdominal aortic aneurysm (AAA) in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
More
This project involves a study of the diameter variation of abdominal aortic aneurysms (AAAs) over the cardiac cycle in vivo, a measure of the in vivo mechanical properties of AAA walls. Patient aneurysms are imaged non-invasively by ECG-gated MR Imaging, then mechanical properties of the aneurysms are determined from computational analysis of the imaging.
More
Abdominal Infection
The purpose of this study is to look at the frequency of neurodevelopmental impairment and long-term gastrointestinal outcomes in premature infants enrolled in the SCAMP study for treatment of complicated intra abdominal infections.
More
Acromegaly
The MACRO registry will collect data prospectively on patients with active acromegaly, defined operationally as an adult patient with a confirmed diagnosis of acromegaly being treated with medical therapy; or eligible to be treated with medical therapy, e.g., having an elevated IGF-1. This is an observational study; therefore, no additional visits or laboratory tests will be required outside of local routine clinical practice. Dosing and duration of medical therapies is at the discretion of the treating physician, in accordance with local labeling.
More
Acute Lymphocytic Leukemia
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile.
More
Acute Myeloid Leukemia
This study aims to learn more about the investigational drug, ASTX727, and another drug, venetoclax, when given in combination. It also aims to evaluate potential pharmocokinetics (PK) interactions for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy.
More
Alcohol Liver Disease
This study is being conducted in patients who are hospitalized due to liver damage from alcohol abuse (Alcoholic Hepatitis AH). The purpose of this study is to see if the study drug, DUR-928 given in inpatient seeting is safe and effective in this group of patients.
More
Alports Syndrome
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More
Alzheimer's Disease
This research study is a 3-week clinical trial of dronabinol, a synthetic form of tetrahydrocannabinol (THC). This study is being done to determine if dronabinol is a safe and effective treatment for agitation symptoms related to Alzheimer’s disease. This study will compare dronabinol to a placebo.
More
Amyloidosis
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: immediate daratumumab + VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2).
More
Anesthesia
Protective tape is used during general anesthesia in order to secure the endotracheal tube with no preference for one or the other. In this study, we will compare two tapes, Durapore™ and Hy-Tape® to determine if one is less likely to cause skin irritation in an effort to improve care for future patients.
More
Aneurysms
The objective of this study is to evaluate the safety and effectiveness of the Surpass Evolve Flow Diverter System in the treatment of unruptured intracranial (brain) aneurysms. If you choose to participate in this study, you will receive intervention with the Surpass Evolve Flow Diverter implant. There will be no randomization or blinding.
More
The primary objective of the study is to determine the optimal intra-arterial drug treatment regimen for arterial lumen restoration after cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome 90 days after patient discharge following in-hospital optimal intra-arterial drug treatment for cerebral vasospasm. This study is a prospective multicenter randomized trial.
More
Anxiety
This is a clinical study that aims to determine the effective dose of music listening duration that is required to reduce anxiety in patients awaiting scheduled cesarean section. It will also compare types of music to accomplish this goal, both of which have been shown effective in prior studies. Methods will involve enrolling and playing music for patients awaiting scheduled C-section, and scoring their anxiety with pre- and post-music questionnaires. Music duration for each subject will be predetermined, and analysis of response will be performed to determine the effective dose 95%, or dose at which there is a 95% chance of subjects having a positive response.
More
Aortic Aneurysm
This is a prospective, multi-center, non-randomized, single arm, post-approval study. The main objective of this study is collection of the real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of abdominal aortic aneurysm (AAA) in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
More
The TRIOMPHE study is designed to further evaluate the safety and efficacy of the NEXUS™ Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, penetrating aortic ulcers and intramural hematoma. NEXUS represents a novel, state-of-the-art technology that provides the unique benefit of endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, PAU and IMH who surgical intervention are not expected to provide suitable benefit, given the associated risks of those procedures.
More
This project involves a study of the diameter variation of abdominal aortic aneurysms (AAAs) over the cardiac cycle in vivo, a measure of the in vivo mechanical properties of AAA walls. Patient aneurysms are imaged non-invasively by ECG-gated MR Imaging, then mechanical properties of the aneurysms are determined from computational analysis of the imaging.
More
Aortic Stenosis
This is a Prospective, multi‐center, international, randomized controlled, post‐market trial. To enroll subjects with symptomatic heart disease due to severe native calcific aortic stenosis and a small annulus appropriate for transcatheter heart valvereplacement therapy. The purpose of this trial is to generate clinical evidence on valve safety and performance of self‐expanding (SE) versus balloon‐expandable (BE) transcatheter aortic valve replacement (TAVR) in subjects with a small aortic annulus and symptomatic severe native aortic stenosis. Devices used in this trial must be commercially approved by the local regulatory agencies in the geography they are used. The devices will be used within the localcommercially approved indication in the geographies in which each device is approved. Subjects will be randomized on a 1:1 basis to receive transcatheter aortic valve replacement (TAVR) with either a Medtronic SE or an Edwards BE TAV. Randomization will be stratified by site and sex. Approximately 700 treated subjects at approximately 90 sites in Canada, EMEA and the United States.
More
The TRIOMPHE study is designed to further evaluate the safety and efficacy of the NEXUS™ Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, penetrating aortic ulcers and intramural hematoma. NEXUS represents a novel, state-of-the-art technology that provides the unique benefit of endovascular treatment of thoracic aortic lesions involving the aortic arch including chronic dissections, aneurysms, PAU and IMH who surgical intervention are not expected to provide suitable benefit, given the associated risks of those procedures.
More
This research is being done to study a potential method of improving blood flow and oxygen delivery to the organs of patients on VA-ECMO. This study involves positioning the return cannula in the aorta, which is the main artery that carries blood away from the heart. We aim to prove that returning oxygenated blood to the aorta is safe and feasible. We also aim to better understand the effects that this method may have on the forces that affect blood flow and heart function.
More
Aortic stenosis (AS) affects over 12.6 million adults and causes an estimated 102,700 deaths annually. When severe AS is untreated, the stenotic valve obstructs blood flow, ultimately leading to pressure overload on the left ventricle, congestive heart failure, and death. Our research is motivated by the observation that undiagnosed severe AS can be deadly. Without treatment, 50% of patients with symptomatic AS will die in 2 years. We previously used machine learning (ML) to develop a system for fully automated AS screening.8 This system offers a novel approach to identifying AS using limited echocardiogram datasets and point-of-care ultrasound device (POCUS). The current knowledge gap and challenge in using ML programs into clinical practice is the lack of clarity in the delivery science behind their implementation. There is a need to address how to integrate ML into clinical practice by designing, implementing and evaluating a system where these novel technologies can be used effectively and the system itself reliably replicated. Our study hopes to address this issue.
More
Aortic stenosis (AS) affects over 12.6 million adults and causes an estimated 102,700 deaths annually. There is interest in novel approaches to identify valve disease earlier the disease course before symptoms occur. We previously used machine learning (ML) to develop a system for fully automated AS screening. Here we are validating the performance of this new method for identifying AS.
More
Appendicitis
This is a multicenter, randomized controlled trial comparing a short vs. long of post-operative antibiotic course in patients with simple or complicated appendicitis based on desirability of outcome ranking (DOOR) using a response adjusted to duration of antibiotic risk (RADAR).
More
Approximately 1/500 pregnant require non-obstetric surgery. Surgical care for the pregnant women raises concern for complications adversely pregnancy outcomes. The most common reason for surgery is acute appendicitis followed by gallbladder disease. Some studies have investigated the impact of a subset of emergency general surgery on maternal outcomes during pregnancy but none have looked at the array of emergency general surgery operations on fetal outcome. In recent decades, the advent of laparoscopic techniques has improved recovery time in the general population and has become the standard of care for some disease processes. Studies have reported safe maternal outcomes for laparoscopic interventions. Despite the common incidence of non-obstetric surgery among pregnant women little is known regarding fetal outcome and the impact of laparoscopic interventions vs. traditional open procedures. Even less is known about the role of nonoperative management of general surgical disease in the pregnant population.
More
Arthritis
This study aims to provide crucial knowledge about the neurobiological mechanisms underlying mind-body therapy for knee osteoarthritis (OA). We will investigate the central mechanism of knee OA pain using brain imaging technology to evaluate how brain function and structure change in response to mind-body exercise over time.
Participants will be randomized to either a Tai Chi or Wellness Education class and asked to come to Tufts Medical Center twice a week for 12 weeks, along with a baseline and follow-up visit (26 study visits). The findings will lead to the establishment of a new treatment paradigm in OA and have broad application to the management of chronic musculoskeletal pain.
More
Juvenile idiopathic arthritis (JIA) is an exclusion diagnosis that encompasses all forms of otherwise unexplained chronic non-infectious arthritis occurring under the age of 16. Various attempts have been made to classify this heterogeneous group of diseases with the aim of identifying mutually exclusive categories suitable for etiopathogenetic studies. Since then increasing evidence has accumulated suggesting that some of these categories are heterogeneous. Therefore, there is a need to revise the criteria in order to identify more homogeneous entities and to try to distinguish those diseases. The main reason for this research study is to learn more about the diagnosis of Juvenile Idiopathic Arthritis (JIA) according to the ILAR (International League of Associations for Rheumatology) criteria and investigate a new classification criteria proposed by the international research organization Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
More
Asperger Syndrome
This qualitative and feasibility study will involve the development, distribution, and evaluation of “period kits” for 15-25 pre-menarchal adolescents with intellectual and developmental disabilities (IDD) (e.g., autism, Asperger’s syndrome, and Down syndrome) in relieving stress and augmenting preparedness concerning menstruation and other imminent pubertal changes.
More
Atopic Dermatitis
Phase 3, randomized, double-blind, placebo-controlled study to assess the impact of lebrikizumab on vaccine immune responses in adult patients with moderate-to-severe atopic dermatitis (AD). This study will evaluate the effect of lebrikizumab treatment on 2 vaccines commonly used in adults with moderate to severe AD
More
Atrial Fibrillation
This clinical investigation is intended to evaluate the safety and effectiveness of Abbott’s AmplatzerTM AmuletTM Left Atrial Appendage (LAA) occluder device (“Amulet device”) compared to commercially available non-vitamin K antagonist oral anticoagulant (NOAC) drugs in patients with non-valvular atrial fibrillation (AF) who are at increased risk for ischemic stroke and who are tolerant of long-term NOAC therapy. The Amulet device is intended to reduce the risk of thromboembolism from the LAA in patients with non-valvular AF who are at increased risk for ischemic stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores, and offers an alternative to oral anticoagulants (OAC) for patients recommended for anticoagulation therapy.
More
The main objective of this study is to compare the time of first detection of atrial fibrillation lasting > 5 minutes using an Abbott insertable cardiac monitor (ICM) compared to non-ICM monitoring in symptomatic heart failure patients.
More
The main objective of this study is to prospectively evaluate the effect of prophylactic intra-operative ventricular tachyarrhythmia ablation (VTA) at the time of left ventricular assist device (LVAD) implantation on post-implant total recurrent VTA events, after accounting for the competing risk of death, from discharge to an average follow-up of 18 months (with a minimum of 9 months) after LVAD implantation.
More
Autism
Racial and ethnic minority families receive less family-centered care than their majority counterparts, resulting in disparities in treatment engagement and adverse child outcomes among children diagnosed with Autism Spectrum Disorder (Autism). Shared-decision making (SDM) increases family-centered care by identifying treatments that meet the needs and goals of the family, and increases engagement, adherence and outcomes. In the context of Autism, a valuable opportunity to engage families in SDM occurs at their first diagnostic encounter, where treatment options are initially discussed. The proposed stakeholder engaged T2 pilot project, draws upon qualitative and quantitative mixed methods to produce objective information about SDM in the context of Autism diagnosis and treatment. This innovative project will aim to identify key elements of SDM during initial diagnostic encounters, explore patient perspectives and the role of race/ethnicity, and investigate provider perspectives in their use of SDM with families. Through direct observation, measurement scales, and qualitative interviews, we will identify the frequency of SDM elements used between 30 parent-provider dyads, as well as information about family preferences, values, and treatment goals for children with Autism, and particularly how they vary by race/ethnicity. Knowledge gained from this foundational research will result in several translational funding opportunities for future SDM interventions: decision aids, provider/parent training, and care system redesign. Our ultimate goal is to increase the use of SDM in clinical practice to provide a system of care for Autism that more fully considers the preferences, values, and treatment goals of families, regardless of their racial/ethnic background.
More
This qualitative and feasibility study will involve the development, distribution, and evaluation of “period kits” for 15-25 pre-menarchal adolescents with intellectual and developmental disabilities (IDD) (e.g., autism, Asperger’s syndrome, and Down syndrome) in relieving stress and augmenting preparedness concerning menstruation and other imminent pubertal changes.
More
Back Pain
Researchers at Tufts Medical Center are conducting a study on the benefits of mepivacaine in neuraxial anesthesia for certain neurosurgical procedures. The purpose of this study is to see if mepivacaine, a local anesthetic, can shorten your time in the recovery room/hospital; decrease the amount of time before you can walk after surgery; allow you to urinate sooner after surgery; and reduce any nausea and vomiting that you might experience after anesthesia and surgery.
More
Birth Control
This is a study to determine if a video that utilizes a peer to teach self administration of subcutaneous depot medroxyprogesterone is both effective and well accepted by adolescent patients who are already receiving ongoing treatment with depot medroxyprogesterone by a medical provider via an inter muscular injection. Self administration can be done at home and therefore offers an alternative to traveling to a medical office.
More
Bladder Cancer
This research is to determine the performance characteristics of a urine-based test for the detection of recurrent bladder cancer in low-grade patients who have been treated according to standard practice and are undergoing routine surveillance cystoscopy. The cystoscopy is regarded as the gold standard for determining recurrence of cancer. The Co-Principal Investigator at Tufts University has developed a urine-based monitoring test of bladder cancer, using imaging of the surface of cells extracted from the patients’ urine. The imaging is going to be done using an advanced sub resonance tapping mode of Atomic Force Microscopy (AFM). The collected images will be analyzed by means of machine learning methods. This may allow for faster, non-invasive, and more reliable detection of bladder cancer.
More
Bladder Diseases
Men with severe symptoms of bladder outlet obstruction often have associated bladder fibrosis leading to diminished bladder contractility. Planning to perform a pilot study using 10 urine samples from controls without urinary symptoms and from 10 men with severe urinary symptoms as noted on the International Prostate Symptom Score (IPSS) questionnaire. Assays will determine levels of collagen within the urine samples from both groups.
More
Bone Marrow Transplantation
The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in patients that have a primary immunodeficiency disorder with no prior stem cell transplant.
More
Brain Cancer
This study is being done to answer the following question: Can a patient’s life be extended by adding a type of radiation therapy called whole-brain radiation therapy that avoids the hippocampus to preserve memory plus the medication memantine that is FDA approved to treat dementia to the usual treatment?
This study aims to find out if adding Hippocampal-Avoidant Whole Brain Radiotherapy and memantine is better or worse than the usual approach for your brain cancer.
More
Brain Contusion
The primary objective of this study is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo. Secondary objectives and endpoints for the study are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion by examining differential effects on hematoma and edema expansion, and to determine if BIIB093 improves survival at Day 90 when compared to placebo.
More
Breast Cancer
This is a research study to test the combination therapy with the study drug ribociclib (Kisqali) and approved breast cancer drug letrozole or fulvestrant, in the treatment of subjects with hormone receptor positive metastatic breast cancer from different racial groups.
The study aims to determine the pharmacological and biochemical association between ribociclib exposure and CYP3A variants in African American/Blacks and Non-Hispanic White patients.
The findings should allow clinicians to tailor treatments to maintain therapeutic doses while limiting toxicities.
More
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.
More
This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing human epidermal growth factor receptor 2 (HER2)-positive breast cancer from returning?
This study aims to find out if this approach is better or worse than the usual approach for human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
More
This ComboMATCH phase II trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone.
More
Approximately 230,000 women are diagnosed with invasive breast cancer and 60,000 women are diagnosed with ductal carcinoma in situ (DCIS) (breast cancer in the breast milk ducts) annually in the US. Most women choose to be treated with breast conserving surgery (BCS). The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer, and to minimize the volume of tissue removed, thereby preserving the overall shape and appearance of the breast. The Standard of Care (SoC) technique for such patients is wire localization, in which a wire is pre-operatively placed near the tumor under mammographic, ultrasonic, or MRI guidance. Wire localization suffers from several limitations. It adds another procedure prior to surgery, complicating and lengthening the process and complicating scheduling. It can be uncomfortable for the patient. Its biggest limitation is inaccuracy. Wire localization requires the surgeon to estimate the three-dimensional (3D) position of the cancer from two-dimensional (2D) mammography images. As a result, positive margins are common after partial mastectomy for non-palpable cancer and DCIS. The aim of this study is to assess whether a device called the Breast Cancer Locator (BCL) can be used during the time of breast cancer removal surgery, and to assess its efficacy, when compared to the SoC group, as defined by the amount of cancer cells remaining in tissue, while assessing the safety of BCL over a period of 6 weeks post-operation.
More
Bullous Pemphigoid
To demonstrate that dupilumab is superior to placebo in achieving sustained remission off oral corticosteroids (OCS) in patients with bullous pemphigoid (BP)
More
Cancer
The use of oral anti-cancer medication to treat cancer has been increasing over time and is expected to continue to increase in the future. The use of these medicines can be challenging for patients and their families, their clinical team, and health care systems. Because these medications are administered at home, patients and their families are responsible for taking the medicines when they are supposed to, safely handling and storing the medicines, and knowing how to check for side effects. This study will ask questions to understand more about patient experiences with oral anti-cancer medication so we can develop programs to improve our support and education of patients in the future.
More
The objective of this study is to evaluate the efficacy of FORE8394 in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.
More
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
More
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
More
The overall aim of this research project is to assess the feasibility and performance of neuropsychological and psychological screening measures completed by adolescents and young adults (AYA), and adults, who receive care at the Reid R. Sacco A YA Cancer Clinic or the Adult Cancer Survivorship Clinic, both at Tufts MC. The AYA Clinic provides cancer survivorship care to individuals between the ages of 18-39 years, while the Adult Clinic serves survivors ages >40. Two screening measures will be assessed: (1) the Montreal Cognitive Assessment (MOCA), a screener for mild cognitive impairment and (2) the Brief Symptom lnventory-18 (BSI), a screener for psychological distress. The results from these well-validated screeners will guide future care for these participants at Tufts MC and beyond.
More
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials.
More
Cancer in Children
The Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) directly addresses the need for the next generation of clinical trials for hepatic malignancies, incorporating rational reductions in therapy that ameliorate both short and long-term side effects for patients with good prognoses while simultaneously optimizing curative potential with intensification and new agent integration to improve outcomes for those with poor prognoses. This trial is the first international cooperative liver tumors trial in which a consensus approach was established by investigators representing Children's Oncology Group (COG), Societe Internationale d'Oncologie Pediatrique - Epithelial Liver Tumor Study Group (SIOPEL) and the Japanese Children's Cancer Group (JCCG). The study builds on treatment strategies established by the most recent trials from each of the individual consortia - COG (AHEP0731 ), SIOPEL (SIOPEL 3 and 4) and Japanese Pediatric Liver Tumor study group (JPLT2), but provides new approaches to all stages of HB and HCC patients keeping the aforementioned goals in focus. A critical aspect of this trial is the opportunity to correlate histologic and biologic heterogeneity with response and outcomes in all risk categories, providing promise for future refinement to the newly proposed risk stratification schema.
More
Cardiac Arrest
This study explores changes in heart function before and after activation of Impella or ECMO devices used to support subjects in cardiogenic shock.
More
Cardiac Failure
The purpose of this study is to determine the relationship between levels of metabolites, such as lactate in the sweat of the skinm, and the severity of heart failure. We hope to determine whether the levels of lactate and other metabolites on the skin change as heart failure severity improves during a hospitalization. This information oculd also be used to develop ways to detect worsening heart failure severity using a sweat-based test. The study seeks to recruit patients admitted to Tufts Medical Center due to decompensated heart failure. There are 2 study visits which each require the collection of 15ml of fasted venous blood, a completed KCCQ, and holding a damped gauze between the palms for 2 minutes. The baseline study visit takes place within 72 hour of admission and the second study visit takes place within 3 and 60 days of the baseline visit when the patient meets criteria for clinical stability.
More
This is a pilot/feasibility study on the accuracy of HRV measured by the Apple Watch on the clinical status of patients admitted for acute heart failure decompensation. We hypothesize that there will be a statistically significant improvement in the HRV that correlates clinically over the course of hospitalization. Meaningful findings from this study will strengthen the potential for a telemonitoring system where HRV measured remotely from home using wearable devices like Apple Watch can help physicians monitoring their health and intervene accordingly.
More
Heart failure is a harmful disease that is associated with high avoidable moribidity that can be treated with a cardiac resynchronization therapy device (CRT-D). Previous studies have shown links between CRT-D implants and reduced rates of morbidity in patients with heart failure with left bundle branch blockages (LBBB). However, there is limited amounts of evidence for the success of heart failure patients with non-LBBB. This prospective, multi-center study is looking at heart failure patients with non-LBBB that are implanted with CRT-D.
More
Many patients with advanced heart failure describe loss of muscle mass and strength in their arms and legs. This process is known as ‘sarcopenia’ and has not been well studied in heart failure. In particular it is unknown whether the sarcopenia process can reverse after a heart failure patient receives a left ventricular assist device (LVAD, a surgically implanted heart pump). Therefore we are partnering with experts in nutrition and body composition at Tufts University to study changes in muscle mass, physical activity, food intake and metabolism in patients receiving an LVAD. Muscle mass is measured by two methods in the study, to help us determine which is the most accurate in heart failure patients: a dual-energy x-ray absorptiometry (DXA) scan and a non-radioactive isotope dilution technique. There are 3 study visits which each take a maximum of 4 hours, performed around the time of LVAD implant (30 days before to 21 days after), and at 3 months and 6 months after LVAD implantation.
More
This study explores changes in heart function before and after activation of Impella or ECMO devices used to support subjects in cardiogenic shock.
More
At Tufts Medical Center, we are continually evaluating different approaches to monitor and improve the care of our patients with advanced systolic heart failure. We are currently partnering with a company that has developed a non-invasive probe that measures capillary oxygenation through the skin. The probe attaches to the skin with a temporary adhesive and records the amount of oxygen in the blood cells passing through the skin. This technology may help us to detect when patients with abnormal heart pumping function (heart failure) are not circulating enough blood to their body. We have designed a study using this non-invasive probe to measure capillary oxygenation during exercise stress tests in patients with systolic heart failure and without systolic heart failure. Both groups of patients will have already been scheduled to undergo a treadmill exercise tests for standard clinical indications at Tufts Medical Center. We attach the adhesive probe to the skin on the base of the thumb and on the forearm during the exercise test. Study participation ends at the conclusion of the stress test, and the adhesive probe is removed. We hope to identify the differences between blood supply to the skin during exercise in patients with normal heart function versus those with systolic heart failure.
More
The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.
Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis
More
Cardiac Sarcoidosis
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
More
Cardiomyopathy
At Tufts Medical Center, we are continually evaluating different approaches to monitor and improve the care of our patients with advanced systolic heart failure. We are currently partnering with a company that has developed a non-invasive probe that measures capillary oxygenation through the skin. The probe attaches to the skin with a temporary adhesive and records the amount of oxygen in the blood cells passing through the skin. This technology may help us to detect when patients with abnormal heart pumping function (heart failure) are not circulating enough blood to their body. We have designed a study using this non-invasive probe to measure capillary oxygenation during exercise stress tests in patients with systolic heart failure and without systolic heart failure. Both groups of patients will have already been scheduled to undergo a treadmill exercise tests for standard clinical indications at Tufts Medical Center. We attach the adhesive probe to the skin on the base of the thumb and on the forearm during the exercise test. Study participation ends at the conclusion of the stress test, and the adhesive probe is removed. We hope to identify the differences between blood supply to the skin during exercise in patients with normal heart function versus those with systolic heart failure.
More
Cardiovascular Disease
Many patients with advanced heart failure describe loss of muscle mass and strength in their arms and legs. This process is known as ‘sarcopenia’ and has not been well studied in heart failure. In particular it is unknown whether the sarcopenia process can reverse after a heart failure patient receives a left ventricular assist device (LVAD, a surgically implanted heart pump). Therefore we are partnering with experts in nutrition and body composition at Tufts University to study changes in muscle mass, physical activity, food intake and metabolism in patients receiving an LVAD. Muscle mass is measured by two methods in the study, to help us determine which is the most accurate in heart failure patients: a dual-energy x-ray absorptiometry (DXA) scan and a non-radioactive isotope dilution technique. There are 3 study visits which each take a maximum of 4 hours, performed around the time of LVAD implant (30 days before to 21 days after), and at 3 months and 6 months after LVAD implantation.
More
Collecting and storing heart tissue and blood samples from consented Tufts Medical Center patients for the purpose of cardiovascular research.
More
The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.
Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis
More
Cervical Cancer
This study is evaluating a newly developed test which will help in detecting a virus that causes cervical cancer for example- high risk human papillomavirus (HR HPV). This test is called Alinity m HR HPV
More
Cervix Disorders
The purpose of the study is to measure the softness of the cervix. The softness of the cervix will be compared in two groups of pregnant women. One group is women who will be having a surgery to strengthen the cervix (a cerclage surgery). The second group is normal women in the prenatal clinic. We anticipate recruiting 140 patients total (60 cases and 80 control patients.)
More
Chronic Kidney Disease
The purpose of this study is to assess the safety and efficacy of an investigational oral drug called difelikefalin, in reducing the intensity of itching and the impact of itch on your quality of life. The FDA already approved a intravenous(IV) form of the drug to treat moderate-to-severe itchiness in people undergoing hemodialysis. This study continues tests the oral form of the drug in reducing itchiness in people not on dialysis. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill.
More
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More
This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
More
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
More
The main aim of this research study is to create materials to make sure that one of the blood
tests we use to measure kidney function are correct. The College of American Pathologists (CAP) surveys
laboratories as part of their proficiency testing program. This survey involves sending out quality control (QC)
samples to clinical laboratories who measure this in patient to make sure that their results are accurate.
More
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN, FSGS, DKD, and Alport Syndrome.
The study is comprised of an optional pre-screening period, screening, treatment, and follow-up periods. If you qualify, you will receive the study drug Atrasentan for up to 1 year.
More
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine.
The study is comprised of an optional pre-screening period, a screening period, a treatment period and a follow-up period. If you qualify, you will receive either the study drug Atrasenten or placebo for up to 2.5 years.
More
The purpose of this clinical trial is to see if the drug Finerenone is safe and effective in patients with in participants with non-diabetic chronic kidney disease. Additionally, while finerenone has been approved for other patient populations, this study will collect additional safety information about finerenone to determine how it affects the body.
More
This study looks at whether the drug GFB-887 (developed by Goldfinch Bio) can slow the progression of kidney disease in patients with FSGS and treatment-resistant minimal change disease. The drug works similarly to drugs called calcineurin inhibitors (aka CNIs, such as tacrolimus or cyclosporine) but without some of the side effects those drugs can have. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill. Once you complete this study, you will have the option to enroll in an additional study where all participants receive the drug.
More
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
More
Chronic Lymphocytic Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
More
Chronic Pain
The purpose of this study is to assess how Immersive Virtual Reality effects the intensity of (pain, tiredness, mood and sensory responses) in people with chronic back pain
- Study participants will complete two Immersive Virtual Reality experiences over two visits to the Virtual Reality Lab at Tufts University
- Study participants will receive up to $80 if all study activities are completed.In addition, participants will be reimbursed up to $40 to cover travel costs.
More
Cirrhosis
The primary objective of this study is to assess the efficacy of rifaximin SSD-40IR versus placebo to delay the occurrence of HE-related hospitalization.
More
You are being invited to consider participation in a clinical research study for patients with cirrhosis caused by nonalcoholic steatohepatitis (NASH) This study involves research and is conducted to determine the safety and efficacy of a new investigational drug called aldafermin (previously known as NGM282
More
Clostridium Difficile Infection
ECOSPOR Ill is a Phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study of the safety, tolerability, and efficacy of SER-109 versus placebo in adult subjects 18 years of age or older with recurrent CDI, defined as: a history of;:: 3 CDI episodes within 12 months, inclusive of the current episode. This study is designed to demonstrate the superiority of SER-109 versus placebo to reduce recurrence of Clostridium difficile infection (CDI) in adults who have received antibacterial drug treatment for recurrent CDI (RCDI), based on the proportion of subjects experiencing a CDI recurrence requiring antibiotic treatment up to 8 weeks after initiation of treatment.
More
ECOSPOR IV is an open-label extension of Study SERES-012. This study is designed to evaluate the safety, tolerability, and efficacy of a SER-109 treatment regimen in adult subjects 18 years of age or older with recurrent Clostridium difficile infection (RCDI), who received a SER-109 or placebo treatment regimen in Study SERES-012.
More
Colon Cancer
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
More
Colorectal Cancer
This is a randomized, double-blind, placebo-controlled, dose-escalating, multi-center study to evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab and To compare the safety and tolerability of ART-123 to placebo in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
More
Corneal Disorders
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
More
The study is designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (dose 1 [5 mg/ml] and dose 2 [15 mg/ml]) in subjects with chronic induced corneal pain (CICP) persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. The study will also determine the optimal dose to carry forward for further development.
More
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.
More
Persistent corneal epithelial defect (PCED) is a persistent non-healing corneal defect or wound. KPI-012 is a novel, human bone-marrow derived human mesenchymal stem cell (hMSC) secretome composed of biologically active components, which have been shown in preclinical studies and early clinical trials to facilitate corneal healing. This study will investigate the efficacy and safety of KPI-012 eye drops 4 times daily for 8-weeks for healing of PCED.
More
Patients that suffered from neuropathic pain or photoallodynia, reported immediate relief of pain after use of TrueTear® intranasal neurostimulator (ITN). We propose a pilot study for treatment of neuropathic corneal pain (NCP) with ITN with the following specific aims:
- To elucidate the efficacy of ITN in ameliorating pain among neuropathic corneal patients.
- To elucidate the safety, efficacy, longevity of ITN in ameliorating pain among neuropathic corneal patients during a 90-day period with daily use.
- o assess quality of life changes by treating neuropathic corneal pain with ITN during a 90-day period with daily use.
More
We will investigate the efficacy of Oxervate treatment in patients with neuropathic corneal pain (NCP). NCP subjects could benefit from its trophic effect on corneal nerves function and its capacity to restore the ocular surface environment. The aim is to investigate the efficacy and tolerability of topical rhNGF cenegermin 0.002% (20mcg/mL) in patients with NCP.
More
The cornea (window in the front of your eye) is made up of many nerves with important regions that allow you to feel sensations like, heat, cold, pressure and vibration. It is well known that many ocular surface disorders, such as dry eye disease (DED), neurotrophic keratitis and post-herpetic neuralgia, affect corneal nerve structure, which can be detected by a special type of eye imaging called ‘In-vivo Confocal Microscopy (IVCM)’. However, the relationship between eye symptoms, signs and abnormal corneal nerve functions are not yet well understood. The quantitative sensory motor test (QST) is a non-invasive method which evaluates nerve function with different stimuli such as cold, heat and vibration. Therefore, people with different corneal conditions who undergo QST may show varying pain responses to each sensation, and may characterize their pain in unique ways. This goal of this study is to find out which types of stimuli have the most impact on ocular discomfort among those with different types of corneal conditions, and compare QST results between ocular surface patients and those without any ocular surface conditions. Most procedures are standard of care which means they are typically performed during a routine eye exam and therefore during your routine clinical visit.
More
Corneal Pain
The study is designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (dose 1 [5 mg/ml] and dose 2 [15 mg/ml]) in subjects with chronic induced corneal pain (CICP) persisting at least for 4 months after refractive surgery and chronicity confirmed during the observational period. The study will also determine the optimal dose to carry forward for further development.
More
Patients that suffered from neuropathic pain or photoallodynia, reported immediate relief of pain after use of TrueTear® intranasal neurostimulator (ITN). We propose a pilot study for treatment of neuropathic corneal pain (NCP) with ITN with the following specific aims:
- To elucidate the efficacy of ITN in ameliorating pain among neuropathic corneal patients.
- To elucidate the safety, efficacy, longevity of ITN in ameliorating pain among neuropathic corneal patients during a 90-day period with daily use.
- o assess quality of life changes by treating neuropathic corneal pain with ITN during a 90-day period with daily use.
More
We propose to develop an economic in-office pain tests that may help screen and differentiate patients with neuropathic corneal pain (NCP) that could be used at any ophthalmic office. These five in-office pain tests include response with filter glasses, moisture googles, cold saline, hypertonic saline and topical proparcaine. The current study will serve as validation for clinical diagnosis of NCP among dry eye disease (DED) patients and will subsequently be conducted in larger population studies. Identification of patients with NCP would prevent unnecessary drug treatment failures and improved response rate of DED patients to therapies, such as Lifitigrast.
More
Covid-19
A multicenter, two arm, randomized, single-blind clinical trial to determine if receiving one dose of convalescent plasma (CP) for mild COVID-19 illness prevents illness progression.
More
This study is being conducted in healthy children from age 6 months to age 12 years. The study is looking at how well the Moderna mRNA vaccine works when given to healthy children for the prevention of COVID-19.
More
The purpose of this study is to provide remdesivir (RDV) to participants with severe COVID-19. The primary objective of this study is to evaluate the efficacy of 2 RDV regimens with respect to the normalization of temperature and oxygen saturation through Day 14.
More
This patient registry aims to recruit people who have recovered following infection with SARS-CoV-2 / COVID-19 for the purpose of connecting them with researchers in the United States who are conducting research to learn about the survivor experience, and develop new treatments for patients currently with the illness.
More
The purpose of the study is to learn about the problems that some individuals who recover from a COVID-19 infection continue to have months after they recover from the initial phase of the infection. We will be performing specific type of imaging called x-ray velocimetry. This allows us to understand regional lung ventilation. We will be examining if the measures of regional lung ventilation are more abnormal in participants who have previously had COVID-19 compared to those who have not previously acquired this infection. We will also investigate if the measurements obtained from x-ray velocimetry correlate with ratings of certain symptoms, quality of life ratings, and results of pulmonary function test and a walking test.
The study includes 1 study visit and will be performed at Tufts Medical Center in Boston, MA.
We expect up to 48 participants will be enrolled in this study at Tufts Medical Center in order to have 40 participants complete the study.
More
This is a research study being conducted in patients who tested positive for COVID-19 in the past 10 days and are admitted to the hospital. The study is being conducted to assess the safety of an experimental drug called Reparixin. This is provided as tablets along with standard treatment to limit progression of Covid-19 disease. This is a randomized, (which means just like tossing a coin, you will be randomly assigned to receive the study drug or the standard treatment) double-blind trial (which means neither you nor the study team will know which group you are assigned to). Details of the study visits are as noted below.
More
This study is looking at the use of famotidine (known as Pepcid AC, an antiulcer medication) and celecoxib (known as CeleBREX, an arthritis medication) as a treatment to help to reduce the symptoms of COVID-19. Participants will be randomly assigned to one of two groups. One group will be given the medications while the other group will be given a placebo with no medical effect.
More
This study is being done to see if a vaccine that is being developed to prevent people from getting sick with COVID-19 is safe and effective and also to see how well it is tolerated. It involves both vaccine and a placebo (which looks like the vaccine but does not contain any actual vaccine).
More
The primary aim of this study is to obtain observational physiological signals from patients previously discharged from hospitalization at Tufts Medical Center between 2019 to present (est enrollment starting in June 2022) with positive diagnosis of COVID-19 to further our understanding and characterization of Long COVID-19 syndrome using combined medical histories and continuous physiological signals captured through wearable devices such as the Oura Ring, Fitbit, AliveCor KardiaMobile, and Samsung Watch3 type devices.
More
While much has been learned about the acute phase of Coronavirus disease 2019 (COVID-19) in the last year, little is known about the recovery phase. There have recently been several reports in the news and in the medical literature about a prolonged recovery phase after developing acute COVID-19 in some individuals who may have persistent symptoms many months after infection, developing the so called “long COVID”. The goal of the proposed study is to determine the underlying cause of impairment in patients who have recovered from COVID-19 but who continue to have symptoms at least 3 months after infection.
More
Participation in this study can be done remotely, from your home. No in-person interactions with the researchers will be needed, and no travel will be required.
To be eligible, contact with the study team needs to be made within 3 days of the time you were tested for COVID-19.
What is the purpose of the study? Coronavirus disease 2019 (COVID-19) is a public health emergency for which there is no known effective treatment. This study will evaluate the study drug, Niclosamide, as a potential treatment for mild to moderate COVID-19 to find out if it is effective in shortening the time that COVID-19 is contagious. This research study will also evaluate if Niclosamide works to shorten the time of symptoms related to COVID-19.
Background: Niclosamide has been widely used in humans to treat tapeworm infections for several decades and is currently listed on the World Health Organization’s List of Essential Medicines, the safest and most effective medicines needed in a health system.
More
ACTIV-1 IM is a master protocol designed to evaluate immune modulators for the treatment of moderately or severely ill hospitalized patients infected with COVID-19. Trial participants will be assessed daily while hospitalized. If the participants are discharged from the hospital prior to Day 29, they will have follow-up study visits at Days 8, 11, 15, 22, and 29. For discharged participants, it is preferred that the Day 8, 11, 15, and 29 visits are in person to obtain safety laboratory tests and blood (serum/plasma) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the participant to return to the clinic. In this case, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The Day 60 assessment will be conducted by phone.
More
The study is seeking to create a repository of blood samples from participants who have a history of testing positive for COVID-19 to help accelerate current and future COVID-19 research.
More
Crohn's Disease
To find out more about children with Crohn’s Disease (CD) to help doctors improve the care of patients with this disease.
More
Cytomegalovirus Infection
Open label trial of letermovir for secondary prophylaxis for solid organ transplant recipients at risk of relapsing cytomegalovirus infection and disease
More
Open label trial of letermovir prophylaxis for those heart transplant recipients at risk of cytomegalovirus infection and disease
More
Dementia
This research study is a 3-week clinical trial of dronabinol, a synthetic form of tetrahydrocannabinol (THC). This study is being done to determine if dronabinol is a safe and effective treatment for agitation symptoms related to Alzheimer’s disease. This study will compare dronabinol to a placebo.
More
Dermatomyositis
This study evaluates the beneficial effect of Octagam 10% given every 4 weeks compared to placebo in subjects with active dermatomyositis. Octagam 10% is an immune globlulin that is administered intravenously. Subjects will be randomly assigned to one of two groups: study drug group that will receive Octagam 10%, or a placebo group that will receive saline solution.
More
Diabetic Eye Problems
This is a 12 month prospective observational study using OCT angiography to visualize retinal ischemia in greater detail in patients with diabetic retinopathy.
More
Diabetic Foot Ulcers
This study will follow a superiority design that will test whether the treatment group (NuShield plus SOC) compared to the control group (SOC alone) demonstrates statistically significant differences for time to and frequency of complete wound closure in patients with diabetic foot ulcers. Subjects in the study will be randomized 1:1 to either: Group 1, NuShield plus SOC weekly for up to 24 weeks, or Group 2, SOC (control) weekly for up to 24 weeks.
More
Diabetic Kidney Problems
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN, FSGS, DKD, and Alport Syndrome.
The study is comprised of an optional pre-screening period, screening, treatment, and follow-up periods. If you qualify, you will receive the study drug Atrasentan for up to 1 year.
More
The purpose of this clincial trial is to see if the drug CSL346 (developed by CSL Behring) is safe and effective in treating type II diabetic kidney disease. We will look at whether the drug decreases the amount of protein in your urine. The drug is given through the vein and under the skin by research nurses under the supervision of the research doctor. This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug.
More
Diabetic Nephropathy
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More
The purpose of this clincial trial is to see if the drug CSL346 (developed by CSL Behring) is safe and effective in treating type II diabetic kidney disease. We will look at whether the drug decreases the amount of protein in your urine. The drug is given through the vein and under the skin by research nurses under the supervision of the research doctor. This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug.
More
This study looks at whether the drug GFB-887 (developed by Goldfinch Bio) can slow the progression of kidney disease in patients with FSGS and treatment-resistant minimal change disease. The drug works similarly to drugs called calcineurin inhibitors (aka CNIs, such as tacrolimus or cyclosporine) but without some of the side effects those drugs can have. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill. Once you complete this study, you will have the option to enroll in an additional study where all participants receive the drug.
More
Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. It also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
More
Dry Eye
The purpose of this research study is to find out more about the study drug, cenegermin 20mcg/mL ophthalmic solution, in people with severe Sjogren’s dry eye disease. The study will see if cenegermin can safely and effectively relieve the signs and symptoms of this condition, and whether it causes side effects. You will be in this research study for 25 weeks (6 months). If you are eligible to participate in the study, you will be asked to self-administer the study eye drops (cenegermin or placebo) 3 times per day (one drop in both eyes every 6-8 hours) for 4 weeks. Once you have finished 4 weeks of using the study eye drops, you will continue in the study for an additional 20 weeks, so your study doctor can monitor your eyes and health for any side effects. You will be asked to continue your Cyclosporine A eye drops during your study duration, which you were taking prior to enrollment.
You will also be asked to attend the eye clinic for 8 visits. These visits can take up to two hours. At each visit, the study team will ask you about your medical history, symptoms and medications. Your study doctor will also conduct an eye examination. All of the eye examination procedures are considered routine for people with severe Sjogren’s DED.
More
The purpose of this research study is to find out more about the study drug, cenegermin 20mcg/mL ophthalmic solution, in people with severe Sjogren’s dry eye disease. The study will see if cenegermin can safely and effectively relieve the signs and symptoms of this condition, and whether it causes side effects. You will be in this research study for 25 weeks (6 months). If you are eligible to participate in the study, you will be asked to self-administer the study eye drops (cenegermin or placebo) 3 times per day (one drop in both eyes every 6-8 hours) for 4 weeks. Once you have finished 4 weeks of using the study eye drops, you will continue in the study for an additional 20 weeks, so your study doctor can monitor your eyes and health for any side effects.
You will also be asked to attend the eye clinic for 8 visits. These visits can take up to two hours. At each visit, the study team will ask you about your medical history, symptoms and medications. Your study doctor will also conduct an eye examination. All of the eye examination procedures are considered routine for people with severe Sjogren’s DED.
More
This prospective, single center, randomized, double-masked, parallel comparison, sponsored study seeks to investigate the efficacy of IDI on ameliorating the signs and symptoms of dry eye disease. The study aims to enroll 54 patients (36 Dextenza commercial formulation, 18 Collagen Plug) with DED.
More
- To establish the prevalence of neuropathic corneal pain in patients with ocular surface discomfort.
- To assess the overlap of neuropathic corneal pain with dry eye disease in patients in diseases that are currently thought to be mutually exclusive.
- To establish the prevalence of subtypes of patients with neuropathic corneal pain or with a neuropathic component of dry eye in patients with ocular surface discomfort.
More
This is a single site, prospective, cross-sectional, controlled clinical study on a total of 66 subjects. The subjects are divided into two groups: HS non-responders (33 subjects) and HS responders (33 subjects). After completion of questionnaires, the subjects will undergo DED testing and functional nerve testing. Subjects who qualify will be dispensed 4 weeks of preservative free artificial tears and instructed to instill one drop into each eye twice daily. Subjects will return for a follow up visit 4 weeks later (± 4 days), during which subjects will complete the questionnaires again and the DED tests and functional nerve tests will be repeated.
More
We will investigate the efficacy of Oxervate treatment in patients with neuropathic corneal pain (NCP). NCP subjects could benefit from its trophic effect on corneal nerves function and its capacity to restore the ocular surface environment. The aim is to investigate the efficacy and tolerability of topical rhNGF cenegermin 0.002% (20mcg/mL) in patients with NCP.
More
This study aims to correlate pediatric dry eye symptomology with electronic device screen time (iPhones, iPads, video games, etc). This study will utilize a modified version of the SPEED questionnaire - a short self-reported survey that asks questions about the way your eyes are feeling and the severity. This questionnaire has been modified to include a section on electronic device screen time usage, to determine if the amount of daily screen time plays a role in the clinical symptomology of dry eye disease.
More
This study is designed to test a potential biomarker to identify NCP patients. A biomarker is a characteristic that is unique to NCP patients and will help to identify them from DED patients so that correct treatment can be provided to them.
More
The cornea (window in the front of your eye) is made up of many nerves with important regions that allow you to feel sensations like, heat, cold, pressure and vibration. It is well known that many ocular surface disorders, such as dry eye disease (DED), neurotrophic keratitis and post-herpetic neuralgia, affect corneal nerve structure, which can be detected by a special type of eye imaging called ‘In-vivo Confocal Microscopy (IVCM)’. However, the relationship between eye symptoms, signs and abnormal corneal nerve functions are not yet well understood. The quantitative sensory motor test (QST) is a non-invasive method which evaluates nerve function with different stimuli such as cold, heat and vibration. Therefore, people with different corneal conditions who undergo QST may show varying pain responses to each sensation, and may characterize their pain in unique ways. This goal of this study is to find out which types of stimuli have the most impact on ocular discomfort among those with different types of corneal conditions, and compare QST results between ocular surface patients and those without any ocular surface conditions. Most procedures are standard of care which means they are typically performed during a routine eye exam and therefore during your routine clinical visit.
More
We propose to develop an economic in-office pain tests that may help screen and differentiate patients with neuropathic corneal pain (NCP) that could be used at any ophthalmic office. These five in-office pain tests include response with filter glasses, moisture googles, cold saline, hypertonic saline and topical proparcaine. The current study will serve as validation for clinical diagnosis of NCP among dry eye disease (DED) patients and will subsequently be conducted in larger population studies. Identification of patients with NCP would prevent unnecessary drug treatment failures and improved response rate of DED patients to therapies, such as Lifitigrast.
More
Emergency Services
A mixed methods study entailing quantitative analysis of a survey distributed among 100 providers in the Tufts Medical Center Emergency Department, defined as Physicians (MD/DO), Physician Assistants (PA), Registered Nurses (RN), Social Workers (SW), and Patient Care Technicians (PCT). Additionally, there will be concurrent qualitative analysis of semi-structured, in-depth interviews with frequent emergency department utilizers, defined as greater-than-or-equal-to 4 ED visits in the past year.
- The first aim is to characterize and examine the lived experience of frequent emergency department utilizers. This will help to understand and analyze the barriers and underlying determinants to overutilization.
- The second aim is to characterize and examine the relationship of emergency department personnel to frequent emergency department utilizers. This will help identify discrepancies in perceived appropriate use between ED personnel and frequent ED utilizers, while also identifying potential precipitants to burnout.
More
Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) causes recurrent corneal abrasions, scarring and vision loss in the majority of patients. Treatment is supportive and there is no cure. One major limitation of therapeutic testing is the lack of established clinical tools for quantifying the severity of corneal disease. Clinicians rely solely on slit lamp exams and subjective reports of frequency and duration of symptoms. These parameters have not been correlated with visual outcomes or any other objective metrics. In the RDEB mouse model, the corneal epithelium is thickened (hypertrophied) in areas of prior injury, blistering or abrasion. It stands to reason that patients with EB may also show epithelial hyperplasia if the ocular surface was recently injured, blistered or abraded. New technology that measures epithelial thickness with anterior segment OCT (AS- OCT) may offer a no-risk, clinically viable tool to quantify severity of disease. Development of this powerful non-invasive tool would allow clinicians to monitor epithelial changes in response to treatments. It could have widespread application for assessment of other diseases of the corneal surface including aniridic pannus and chemical injury.
More
Eye Diseases
Age-related macular degeneration (AMD) is a disease that affects the retina, an integral part of the eye responsible for sensing light and relaying images to the brain. In the United States, AMD is the leading cause of irreversible vision loss as people age. Previous studies have shown that the nutrients lutein and zeaxanthin can help protect against AMD in middle aged and older adults. These nutrients form a pigment in the retina (macular pigment) that helps protect the retina from light damage. The more macular pigment in the retina, the better protection it offers.
Lutein and zeaxanthin are found in foods such as leafy green vegetables, broccoli, peas and avocados. They are also found in pistachio nuts, a bioavailable source of these nutrients. Since most people do not eat pistachio nuts daily, we are trying to see whether eating 2-ounces of pistachio nuts a day can help increase the density or amount of macular pigment in the eye.
More
1. Men or women ≥18+ years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe Non-proliferative Diabetic Retinopathy 2. Treatment-naïve (ie, no previous anti-VEGF or steroid treatment or PRP or laser within 1,000 μm of the foveal center/treatment for macular edema or DR in the study eye) 3. Willing and able to return for all study visits and comply with study-related procedures
More
The study is being conducted to compare whether an optical correction of bifocal spectacle lenses (BFL) or single-vision spectacle lenses (SVL) is more effective for the treatment of children with esotropia greater at near. Children will be randomized to be treated with BFLs or SVLs for 3 years and be evaluated at regular intervals throughout the study to determine whether their condition has worsened. Children whose condition worsens during the study will either start BFL treatment (if randomized to SVL group) or continue BFL treatment (if randomized to BFL group) for 2 months to allow assessment of outcome in BFLs, and then be released to treatment at investigator discretion while continuing in study follow-up. Children whose condition has not worsened during the study will start or continue BFL (depending on treatment group) for 2 months at 3 years. All children return at 38 months to assess binocular function. The effectiveness and safety of both treatments will be compared.
More
Eye Movement Disorders
The study is being conducted to compare whether an optical correction of bifocal spectacle lenses (BFL) or single-vision spectacle lenses (SVL) is more effective for the treatment of children with esotropia greater at near. Children will be randomized to be treated with BFLs or SVLs for 3 years and be evaluated at regular intervals throughout the study to determine whether their condition has worsened. Children whose condition worsens during the study will either start BFL treatment (if randomized to SVL group) or continue BFL treatment (if randomized to BFL group) for 2 months to allow assessment of outcome in BFLs, and then be released to treatment at investigator discretion while continuing in study follow-up. Children whose condition has not worsened during the study will start or continue BFL (depending on treatment group) for 2 months at 3 years. All children return at 38 months to assess binocular function. The effectiveness and safety of both treatments will be compared.
More
Eyelid Drooping
This is a multisite, randomized controlled clinical trial evaluating the effect of local tranexamic acid on post-operative ecchymosis in eyelid surgery. Patients will act as their own controls with one eyelid receiving a control injection of standard local anesthetic whereas the other eyelid will be randomized to receive a mixture of local anesthetic and tranexamic acid. Post-operative ecchymosis will be graded by a masked reviewer using a validated scale.
More
Fallopian Tube Cancer
PICCOLO is a Phase 2, multicenter, open label study designed to evaluate the safety and efficacy of MIRV in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression. Mirvetuximab Soravtansine (MIRV) is an investigational drug designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed for the treatment of subjects with recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
More
Focal Semental Glomeroulsclerosis
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More
This study looks at whether the drug GFB-887 (developed by Goldfinch Bio) can slow the progression of kidney disease in patients with FSGS and treatment-resistant minimal change disease. The drug works similarly to drugs called calcineurin inhibitors (aka CNIs, such as tacrolimus or cyclosporine) but without some of the side effects those drugs can have. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill. Once you complete this study, you will have the option to enroll in an additional study where all participants receive the drug.
More
Gallstones
Approximately 1/500 pregnant require non-obstetric surgery. Surgical care for the pregnant women raises concern for complications adversely pregnancy outcomes. The most common reason for surgery is acute appendicitis followed by gallbladder disease. Some studies have investigated the impact of a subset of emergency general surgery on maternal outcomes during pregnancy but none have looked at the array of emergency general surgery operations on fetal outcome. In recent decades, the advent of laparoscopic techniques has improved recovery time in the general population and has become the standard of care for some disease processes. Studies have reported safe maternal outcomes for laparoscopic interventions. Despite the common incidence of non-obstetric surgery among pregnant women little is known regarding fetal outcome and the impact of laparoscopic interventions vs. traditional open procedures. Even less is known about the role of nonoperative management of general surgical disease in the pregnant population.
More
Gestational Diabetes Mellitus
The use of smartphone applications as gestational diabetes management is an emerging area of research. We are hoping to explore possible benefits of the Malama smartphone app to help manage your blood sugar during pregnancy. We also hope to explore how you recover from gestational diabetes shortly after your baby's birth by asking you to do a blood sugar test (HA1c) and a glucose tolerance test.
Participants will be randomized to using the Malama app to track blood sugars or traditional logs such as pen-and-paper. If assigned to use Malama, you will be asked to complete a patient experience survey.
More
Glaucoma
Eligible subjects are selected from a registry maintained by the Clinical Site: Cornea Research Foundation of America (CRFA) In Indianapolis. Registry patients are individuals who underwent corneal surgery at the Price Vision Group and whose intraocular pressure was tracked over at least a 6-month period following their surgery and follow-up treatment with steroids. The patients" clinical data resides in the registry. Thus, ONLY CRFA registry patients are eligible for recruitment to the study. Selected registry patients that meet all inclusion/exclusion criteria are phoned, the study is explained, and if they agree to participate they are mailed a consent form. The signed form is returned to CRFA by mail. Enrolled subjects are then mailed a saliva collection kit. Patients mail their filled kits to the Laboratory Site, previously USC, now Tufts Medical Center. DNA will be prepared, and DNA analysis will be performed at Tufts Medical Center. DNA will be stored at Tufts Medical Center. Statistical analysis to associate patient clinical data to DNA genotype will be performed at the Statistical Site: the University of Illinois Chicago.
More
Glioblastoma
This is a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study, with the objective of comparing Progression-Free Survival (PFS) in newly diagnosed GBM patients treated with IGV-001 with patients treated with placebo.
More
tilize fresh tumor tissue to aid the development of future therapies for brain cancer.
Briefly, a cell immunotherapy consisting of a patient’s autologous glioblastoma tumor cells, called ‘IGV-001’, is being tested in clinical trials. In order to advance clinical and product development of IGV-001, Imvax is seeking access to patient material to test key product parameters in a laboratory setting.
The device used to collect the tissue, the Myriad multifunctional device enabling suction, resection, and collection of tumor tissue (see NICO Myriad Use Manual) is an FDA-approved device that is safe
More
This is a phase I trial to see whether patients are able to adhere to a modified, high fat/low carbohydrate diet (the sHFLC + KetoPhyt Diet) with a supplement named KetoPhyt that includes ketones and anti-inflammatory properties.
The classic ketogenic diet (KD) is difficult for patients to adhere to due to its stringent nature. A modified KD has been developed that mimics the glucose lowering, ketone raising effects and the anti-cancer outcomes of the KD.
The sHFLC + KetoPhyt diet will be implemented in a cohort of 10 Glioblastoma patients, who will be trained and provided with sample meal plans so as to maintain their carbohydrate levels up to 33% of total caloric intake. The study will determine whether participants can maintain the diet and the ketogenic state.
This study will also conduct molecular analyses to determine the effect of the diet on the microbiome, inflammatory cytokines, and extracellular vesicle content.
More
Glioblastoma Multiforme
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Approximately 210 patients with Glioblastoma Multiforme (GBM) after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of overall survival
In this research study, an investigational medication named berubicin is being compared to lomustine (an approved chemotherapy medication) for the treatment of recurrent GBM.
The main purpose of this study is to investigate how effective berubicin is in treating GBM that has recurred after initial standard therapy, and comparing this with lomustine. The study also aims to assess the safety of berubicin and how it is absorbed by and cleared from the body. Both medications are designed to slow or stop the growth of cancer cells.
More
Glomerular Disease
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More
This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
More
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN, FSGS, DKD, and Alport Syndrome.
The study is comprised of an optional pre-screening period, screening, treatment, and follow-up periods. If you qualify, you will receive the study drug Atrasentan for up to 1 year.
More
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
More
Grave's Disease
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Hashimoto's Thyroiditis
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Head and Neck Cancer
This trial will help to determine if either the experimental arm (adjuvant reirradiation plus pembrolizumab, followed by pembrolizumab to complete 12 months total of pembrolizumab and/or pembrolizumab alone for 12 months) significantly improves Overall Survival (OS) compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk patients.
More
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that has spread to other places in the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.
More
Health and Work
The purpose of this research is to study whether our program, called Community Walks, works to promote physical activity.
More
Healthy Volunteers
Researchers at Tuft Medical Center are looking for healthy volunteers to join a study of an investigational drug that may kill ticks and prevent Lyme disease.
More
Blood Pressure Imager (BPI), which is a new technology that does not require cuffs or expensive equipment, and can be used by untrained individuals at their own homes or regional care settings to measure blood pressure. In this study, blood pressure will be measured with BPI and blood pressure readings will be compared with a commercially available cuff-based BP measuring device.The BPI will be placed at the wrist of healthy volunteers or persons with history of high blood pressure with the help of a wrist strap- similar to the current heart-rate monitoring devices in the market, such as the Fitbit- and three sets of readings will be obtained.
More
This project involves a study of the diameter variation of abdominal aortic aneurysms (AAAs) over the cardiac cycle in vivo, a measure of the in vivo mechanical properties of AAA walls. Patient aneurysms are imaged non-invasively by ECG-gated MR Imaging, then mechanical properties of the aneurysms are determined from computational analysis of the imaging.
More
The purpose of this study is to investigate the treatment sensitivity of the multi-item DBR scales (a hybrid between rating scales and direct observation) (henceforth referred to as "DBR-MIS'') through a series of single-case intervention studies. That is, we wish to examine whether the DBR-MIS measures are sensitive to changes in student behavior. The single-case studies will use an A-B design across subjects to evaluate the effects of medication intervention on internalizing behaviors ( e.g., worries, sad), social behaviors (e.g., reluctant to join others, avoidant), and externalizing behaviors (e.g., disruptive, oppositional). It is hypothesized that changes in these behaviors will be reflected in the DBR-MIS ratings completed by classroom teachers and the students themselves (if age 8 and above). Secondary aims include looking at teacher and student concordance on the DBR-MIS measures in the instances when both the teacher and the student ( of appropriately determined age) will be completing the brief rating scales.
More
The purpose of this research is to study whether our program, called Community Walks, works to promote physical activity.
More
This study focuses on developing a new portable noninvasive system to aid in the diagnosis of the vision disorders Multiple Sclerosis and Optic Neuritis. This device combines images and patterns using a Head Mounted Display, similar to a virtual reality headset. The system measures brain responses to these images using a form of electroencephalography (EEG), which will give us information about how the brain and eyes communicate and how this may be affected by a vision disorder.
More
Heart Diseases
This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More
The Global cVAD Registry collects data retrospectively from hospital medical records for patients, who received one or multiple Impella devices during routine care. This registry is an observational, multicenter, retrospective records review. The purpose of this registry is to capture data that reflects 'real world' use of Impella devices in clinical practice and provide insight into patient characteristics, overall health, patterns of care, quality of care and performance during the hospital stay.
More
The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.
Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis
More
The primary objective for this early feasibility study is to assess safety and feasibility of the Impella ECP device in adult patients undergoing an elective high-risk percutaneous coronary intervention. To assess safety, special attention is being paid to the effect of the pump on the aortic valve
More
Heart Failure
The purpose of this study is to determine the relationship between levels of metabolites, such as lactate in the sweat of the skinm, and the severity of heart failure. We hope to determine whether the levels of lactate and other metabolites on the skin change as heart failure severity improves during a hospitalization. This information oculd also be used to develop ways to detect worsening heart failure severity using a sweat-based test. The study seeks to recruit patients admitted to Tufts Medical Center due to decompensated heart failure. There are 2 study visits which each require the collection of 15ml of fasted venous blood, a completed KCCQ, and holding a damped gauze between the palms for 2 minutes. The baseline study visit takes place within 72 hour of admission and the second study visit takes place within 3 and 60 days of the baseline visit when the patient meets criteria for clinical stability.
More
This is a pilot/feasibility study on the accuracy of HRV measured by the Apple Watch on the clinical status of patients admitted for acute heart failure decompensation. We hypothesize that there will be a statistically significant improvement in the HRV that correlates clinically over the course of hospitalization. Meaningful findings from this study will strengthen the potential for a telemonitoring system where HRV measured remotely from home using wearable devices like Apple Watch can help physicians monitoring their health and intervene accordingly.
More
his study is designed to evaluate the safety and efficacy of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
More
This study will examine how effective the SyncAV feature of Abbott’s cardiac resynchronization therapy device is in treating heart failure.
More
Heart failure is a harmful disease that is associated with high avoidable moribidity that can be treated with a cardiac resynchronization therapy device (CRT-D). Previous studies have shown links between CRT-D implants and reduced rates of morbidity in patients with heart failure with left bundle branch blockages (LBBB). However, there is limited amounts of evidence for the success of heart failure patients with non-LBBB. This prospective, multi-center study is looking at heart failure patients with non-LBBB that are implanted with CRT-D.
More
Many patients with advanced heart failure describe loss of muscle mass and strength in their arms and legs. This process is known as ‘sarcopenia’ and has not been well studied in heart failure. In particular it is unknown whether the sarcopenia process can reverse after a heart failure patient receives a left ventricular assist device (LVAD, a surgically implanted heart pump). Therefore we are partnering with experts in nutrition and body composition at Tufts University to study changes in muscle mass, physical activity, food intake and metabolism in patients receiving an LVAD. Muscle mass is measured by two methods in the study, to help us determine which is the most accurate in heart failure patients: a dual-energy x-ray absorptiometry (DXA) scan and a non-radioactive isotope dilution technique. There are 3 study visits which each take a maximum of 4 hours, performed around the time of LVAD implant (30 days before to 21 days after), and at 3 months and 6 months after LVAD implantation.
More
This is a Prospective, multicenter, randomized, parallel-controlled, open-label two arm trial with an adaptive design. Eligible subjects will be randomized in a 1:1 ratio to PCI with Impella CP® (Intervention Group) versus standard of care PCI with or without IABP (Control Group). Approximately 1252 subjects will be randomized in a 1:1 ratio to PCI + Impella vs. PCI ± IABP.
The objective is to demonstrate that in high-risk patients with complex CAD and reduced left ventricular function undergoing PCI, PCI with Impella MCS is superior to PCI without Impella MCS in reducing the composite rate of all-cause death, stroke, MI or hospitalization for cardiovascular causes at 3-year follow-up.
All subjects will have follow-up for 3 years after randomization. The primary endpoint will be assessed after the last randomized patient reaches 1-year follow-up.
Eligible subjects are those with a chronic coronary syndrome (CCS) or NSTEMI with LVEF 40% or STEMI ≥24 hours and <30 days after symptom onset with LVEF 30% in whom complex PCI is planned after heart team discussion, without any study Exclusion Criteria and who provide informed written consent for participation in the Trial. Prior to randomization, all subjects will undergo baseline transthoracic echocardiography, QoL assessment, 6MWD testing (if able to ambulate). Randomization will take place in the Cardiac Catheterization Lab. Prior to randomization in the Cath Lab, the PCI operator will declare 1) the intended revascularization plan regardless of the use of hemodynamic support (including vessels/lesion, staging and intended IABP use); 2) the intent to use (or not use) IABP if randomized to the Control arm; 3) the planned use of right heart catheterization either within or not within a formal sub-study or not at all. Patients will then be randomized to PCI with Impella CP or standard of care PCI (± IABP),treatment of patients and discontinuation of hemodynamic support will be based on Protocol recommendations and standard of care at the hospital site, but Impella removal in the Cath lab is mandated.
More
This study is looking at patients who will be receiving the HeartMate3 Left ventricular assist device and its insertion based off of an incision technique aside from full median sternotomy.
More
The purpose of this randomized study is to evaluate the safety and effectiveness of EVAHEART 2 Implantable Left Ventricular Assist System (EVA2 LVAS) by demonstrating non-inferiority to HeartMate 3 when used for the treatment of advanced, refractory, New York Heart Association Class IV heart failure.
More
Cardiogenic shock (CS) is a dangerous clinical condition where the heart’s ability to pump blood is so compromised that it cannot support the vital functions of the rest of the body. CS has an increased risk of death of 50-60%, and despite tremendous research effort over the last decade, survival outcomes have not changed over this period. Current treatment for CS often involves mechanical circulatory support (MCS) devices, which are mechanical pumps that help support blood flow to the body. These devices primarily support left ventricular (LV) heart function (the function of the main chamber of your heart). However, many patients with CS have right ventricular (RV) dysfunction as well, which is difficult to manage and associated with shortened lifespan. Better recognition and management of right ventricular (RV) failure is therefore critical for improving clinical outcomes in CS. This research will use a new way to measure RV afterload, which is the force resisting the ejection of blood from the RV. We hope that by using this new method, we can better understand how to treat future patients with CS.
More
The proposed dyadic intervention will be one of the first to target the outcomes of both the HF patient and their spouse care partner simultaneously through a team-based intervention centered on shared appraisal, collaboration, communication and confidence to promote optimal dyadic health. The proposed study is, therefore, significant in addressing an important gap. Our study will determine the feasibility, acceptability and clinical meaningfulness of the Taking Care of Us program, providing vital information needed to move closer to our long-term goal to successfully translate this program into multiple delivery modalities (for maximum reach) and inform clinical practice. Results of this study will provide vital information to move us closer to translating successful programs into clinical practice and shed important light on whether, for whom, and how the Taking Care of Us program benefits both members of the HF care dyad
More
This is a pilot, multinational, multicenter, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of males or females 18 to 85 years of age, hospitalized for acute decompensated heart failure (ADHF) with persistent hypotension (systolic blood pressure [SBP] 70-100 mmHg for two hours) and heart rate 75 to 150 beats/minute. The primary objective of this study is to assess the ability of istaroxime to increase SBP in patients with cardiogenic shock (CS) or pre-shock (Society for Cardiovascular Angiography & Intervention (SCAI) Stages A and B), defined as hospitalization for ADHF with persistent hypotension (SBP 70-100 mmHg for two hours) who currently, and since admission to the hospital and throughout Screening, have not received IV vasopressors, inotropes, or digoxin, or not on cardiovascular, respiratory, or renal mechanical support.
More
Severe skeletal muscle loss (wasting) and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low or high dose protien supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothesize that skeletal muscle wasting in HFrEF is promoted by neurohumoral activation of catabolic metabolism (such as GDF-15 and ActRII pathways) and can be at least partially reversed by increased dietary protein intake. It is anticipated that this study will determine whether dietary protein supplementation helps to prevent muscle wasting and will advanced understanding of the GDF-15 and ActRII muscle wasting pathways.
More
This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More
The main objective of this study is to compare the time of first detection of atrial fibrillation lasting > 5 minutes using an Abbott insertable cardiac monitor (ICM) compared to non-ICM monitoring in symptomatic heart failure patients.
More
Malnutrition and unintentional weight loss are highly prevalent among patients with heart failure (HF), with approximately 50% of patients with heart failure meeting malnutrition criteria. Poor dietary quality and micronutrient deficiencies are associated with higher rates of HF hospitalization and mortality. Therefore nutritional interventions to improve dietary quality and prevent malnutrition development may represent an effective strategy to improve HF-related health status and survival outcomes. To date, there are no large clinical trials investigating the efficacy of ‘food as medicine’ to improve morbidity and mortality for patients with heart failure with reduced ejection fraction (HFrEF). We plan to conduct a single-center, randomized pilot trial to assess the tolerability, feasibility, and efficacy of providing medically-tailored meals (MTMs) to patients with HFrEF and malnutrition. We hypothesize that home delivery of MTMs will be feasible, well-tolerated and achieve a high degree of satisfaction for patients with HFrEF. The first phase of the proposed pilot study will asssign participants to a 12-week MTM phase only. The second phase is a randomized crossover trial, in which each subject receives a 12-week standard of care phase with self-directed dietary intake and a 12-week MTM dietary intervention phase, with a 4-week washout period between the two phases. Meals will be designed, prepared and delivered by our community based organized partner, Community Servings. We will measure HF-related health status, functional capacity, and biomarkers of heart failure and nutritional status before and after each study phase. The proposed study will facilitate a larger future randomized trial of MTM for patients with HFrEF and malnutrition, powered to examine the impact on HF hospitalizations and mortality.
More
At Tufts Medical Center, we are continually evaluating different approaches to monitor and improve the care of our patients with advanced systolic heart failure. We are currently partnering with a company that has developed a non-invasive probe that measures capillary oxygenation through the skin. The probe attaches to the skin with a temporary adhesive and records the amount of oxygen in the blood cells passing through the skin. This technology may help us to detect when patients with abnormal heart pumping function (heart failure) are not circulating enough blood to their body. We have designed a study using this non-invasive probe to measure capillary oxygenation during exercise stress tests in patients with systolic heart failure and without systolic heart failure. Both groups of patients will have already been scheduled to undergo a treadmill exercise tests for standard clinical indications at Tufts Medical Center. We attach the adhesive probe to the skin on the base of the thumb and on the forearm during the exercise test. Study participation ends at the conclusion of the stress test, and the adhesive probe is removed. We hope to identify the differences between blood supply to the skin during exercise in patients with normal heart function versus those with systolic heart failure.
More
The purpose of the study is to develop risk profile for unplanned or urgent healthcare use for symptoms of Heart Failure (HF). Patients with HF are hospitalized frequently to manage increasing symptoms. It is important to identify and treat those at highest risk for readmission.
More
The main objective of this study is to prospectively evaluate the effect of prophylactic intra-operative ventricular tachyarrhythmia ablation (VTA) at the time of left ventricular assist device (LVAD) implantation on post-implant total recurrent VTA events, after accounting for the competing risk of death, from discharge to an average follow-up of 18 months (with a minimum of 9 months) after LVAD implantation.
More
This study explores changes in blood flow in the kidney before and after activation of Impella or ECMO devices, used to support subjects in cardiogenic shock.
More
The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.
Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis
More
This is a prospective, multi-center, single-arm, early feasibility study that aims to evaluate the safety of the Impella BTR™ in adult patients requiring left-ventricular hemodynamic support, and to evaluate the effectiveness of the Impella BTR™ in supporting patients to recovery or their next therapy.
More
Heart Transplantation
Multi-center, observational post-approval registry to compare patient and graft survival of adult primary heart transplant recipients receiving DBD donor hearts perfused and assessed on the OCS Heart System compared to adult recipients of DBD donor hearts preserved using ischemic cold storage hearts (Control) at the same Registry centers over the same time period. The objective of this post-approval registry is to provide additional real-world evidence of the performance of the OCS Heart System to preserve DBD donor hearts.
More
This study is designed to find out whether there is a difference between how men and women respond to infections or vaccines following heart transplantation. We are recruiting men and women undergoing heart transplantation to participate by providing three blood samples over the course of about six months (taken in the same time and place as usual blood draws used for clinical purposes). We will use these samples to test levels of cells and proteins that are used fight infection and will compare these levels between male and female patients. In addition, we will gather information over the course of the first six post-transplant months about any infections or episodes of heart transplant rejection that you may experience. The point of the study is to identify if there could be different strategies used to prevent or treat infection in male versus female transplant recipients.
More
Hematologic Disorders
This study explores changes in blood flow in the kidney before and after activation of Impella or ECMO devices, used to support subjects in cardiogenic shock.
More
Hematologic Malignancies
This is an open-label, multi-center Phase 1 study of LOXO-338 in patients with advanced hematologic malignancies who have received standard therapy. This study will be conducted in 2 parts. Part 1 will evaluate LOXO-338 as monotherapy. If safety and initial evidence of efficacy of LOXO-338 monotherapy are confirmed, Part 2 will evaluate the combination of LOXO-338 with LOXO-305.
More
PBCAR19B-01 is a Phase 1, first-in-human study of PBCAR19B designed to evaluate the safety and tolerability of PBCAR19B in subjects with relapsed/refractory Non Hodgkin Lymphoma (r/r NHL) and find an appropriate dose to optimize safety and efficacy.
More
Hepatitis C
With the advent of well-tolerated highly-curative treatment, eradication of hepatitis C virus (HCV) from the United States is possible. Despite guidelines, high HCV prevalence (18-85%, depending on the state) and modeling demonstrating cost-effectiveness, HCV care in corrections’ systems is infrequent. Racial and ethnic minorities comprise the majority (>60%) of HCV cases in US correctional settings. Overlaid on health disparities imposed by incarceration, there are racial disparities in corrections’ settings as evidenced by higher rates of HCV-related morbidity and mortality in incarcerated Non-Whites than Whites.
Increasing access to HCV testing during incarceration with linkage to HCV treatment in the community following release is a feasible approach to decrease health disparities. Recognizing the gaps in knowledge about HCV testing and opportunities for improvement, I have partnered with key stakeholders along the HCV care pathway to evaluate the current state of HCV testing in MA jails. My goal is to interview inmates and other stakeholders (including people who work and people in the community who help deliver care to people who are in jail) to betterat the jail understand barriers and facilitators to testing and treatment in the jails. Examples of important stakeholders include anyone who makes decisions about Hep C testing and treatment for people in jail. This included sheriffs, clinicians, public health specialists, pharmacists, industry representatives.
More
Hepatoblastoma
The Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) directly addresses the need for the next generation of clinical trials for hepatic malignancies, incorporating rational reductions in therapy that ameliorate both short and long-term side effects for patients with good prognoses while simultaneously optimizing curative potential with intensification and new agent integration to improve outcomes for those with poor prognoses. This trial is the first international cooperative liver tumors trial in which a consensus approach was established by investigators representing Children's Oncology Group (COG), Societe Internationale d'Oncologie Pediatrique - Epithelial Liver Tumor Study Group (SIOPEL) and the Japanese Children's Cancer Group (JCCG). The study builds on treatment strategies established by the most recent trials from each of the individual consortia - COG (AHEP0731 ), SIOPEL (SIOPEL 3 and 4) and Japanese Pediatric Liver Tumor study group (JPLT2), but provides new approaches to all stages of HB and HCC patients keeping the aforementioned goals in focus. A critical aspect of this trial is the opportunity to correlate histologic and biologic heterogeneity with response and outcomes in all risk categories, providing promise for future refinement to the newly proposed risk stratification schema.
More
Hepatology
This study is being conducted in patients who are hospitalized due to liver damage from alcohol abuse (Alcoholic Hepatitis AH). The purpose of this study is to see if the study drug, DUR-928 given in inpatient seeting is safe and effective in this group of patients.
More
Herpes Zoster
This study is a double-masked, placebo controlled randomized clinical trial looking to find out whether one year of a low dose of the medicine valacyclovir reduces complications of shingles affecting the eye.
More
Hidradenitis Suppurativa
4 year long term extension study for subject who participated in previous HS study
More
High Blood Pressure
Blood Pressure Imager (BPI), which is a new technology that does not require cuffs or expensive equipment, and can be used by untrained individuals at their own homes or regional care settings to measure blood pressure. In this study, blood pressure will be measured with BPI and blood pressure readings will be compared with a commercially available cuff-based BP measuring device.The BPI will be placed at the wrist of healthy volunteers or persons with history of high blood pressure with the help of a wrist strap- similar to the current heart-rate monitoring devices in the market, such as the Fitbit- and three sets of readings will be obtained.
More
High Blood Pressure in Pregnancy
Understanding the etiology of preeclampsia and spontaneous preterm delivery through the characterization of placental trophoblasts and maternal decidual leukocytes as well as their interactions
More
Hypertension
Accurate resting blood pressure plays an important role in the accurate calculation of flow-dependent valvular indices used to grade the severity of valvular disease using echocardiograph images. If resting blood pressure is over-estimated there is a potential for error in the diagnosis of valvulopathies and by extension, an over or under treatment of valvular disease. Therefore, there is a need to improve concordance between various non-flow dependent indices, such as AVA and Dimensionless Index (DI), and flow dependent indices by using the patient’s average resting BP or trough BP. It is still not known at what time point during the course of the study the patient achieves their resting BP. This research study hopes to investigate that.
More
Blood Pressure Imager (BPI), which is a new technology that does not require cuffs or expensive equipment, and can be used by untrained individuals at their own homes or regional care settings to measure blood pressure. In this study, blood pressure will be measured with BPI and blood pressure readings will be compared with a commercially available cuff-based BP measuring device.The BPI will be placed at the wrist of healthy volunteers or persons with history of high blood pressure with the help of a wrist strap- similar to the current heart-rate monitoring devices in the market, such as the Fitbit- and three sets of readings will be obtained.
More
Hypertrophic Cardiomyopathy
This study is a double-blinded phase 2 clinical trial for a medication dedicated to treating patients with non-obstructive hypertrophic cardiomyopathy.
More
Inflammatory Bowel Disease
This study will examine the colonic microbes and genes in patients with active ulcerative colitis compared to patients with ulcerative colitis in remission.
More
This study is looking at home cooking patterns in people seen at the Tufts GI clinic with IBD and those without IBD. Participants will be given a questionnaire that will ask about different parts of the participants' home cooking patterns including attitudes, self-efficacy, and knowledge. By taking the responses to the questionnaire, we plan to examine different variables linked to home cooking pattern and how they differ between people seen at the GI clinic here at Tufts with IBD, and people seen at the clinic without IBD.
More
Intensive Care
This study aims to compare the effects of inhaled isoflurane sedation with the standard of care IV sedative propofol. Patients enrolled on this study will be on a ventilator (breathing machine) for more than 12 hours and require continuous sedation to keep the patient comfortable which can range from a state of drowsiness and relaxtion to a state of unconsciousness. The study drug, inhaled isoflurane, has been approved for use during surgery and is routinely used in this setting but this study will evaluate the drug as a general ICU sedative and it will be delivered through the Sedaconda ACD-S device which connects to the breathing tube.
More
A randomized, controlled, open-label, multi-center adaptive clinical trial to investigate the safe and effective performance of the Lungpacer Diaphragm Pacing Therapy System in patients who have failed to wean from mechanical ventilation
More
This is a survey of parents whose children are admitted to the PICU, investigating how life stressors impact the time they spendin the hospital during their child's PICU stay. To the best of our knowledge, no previous research has assessed the vovariance of parental stressors within and outside the hospital environment with the amount of time parents spend within the PICU. We hypothesize that secondary stressors such as work obligations, child care needs, financial stress, family medical needs, and distance from home, as well as comfort within the hospital will show correlation with time spent within the PICU for parents.
More
The objective of this study is to demonstrate that the OptiScanner® can identify elevated and changing blood lactate levels in surgical ICU subjects.
More
Interstitial Lung Diseases
This is a long-term extension (LTE) follow up study where recruitment of subjects will continue as the parent study (AV-101-002) progresses from Phase 2b to Phase 3. Subjects who were on placebo in Phase 2b and the Intermediate Part of the study who enroll in the LTE study will be re-randomized to one of the 3 active AV-101 doses until such time as the optimal dose has been selected. Once the optimal dose of AV-101 has been selected, all subjects will be transitioned to the optimal dose while they continue in the LTE, and subjects completing the Intermediate Part or parent study Phase 3 will enroll into the LTE study at the optimal dose.
More
This is a Phase 2 study investigating safety and tolerability of Inhaled Treprostinil in participants with Pulmonary Hypertension associated with Interstitial Lung Disease.
More
Intraabdominal Infections
The purpose of this research study is to determine if IV sulopenem followed by oral sulopenem-etzadroxil/probenecid is safe and at least as effective as standard treatment for complicated intra-abdominal infections
More
Intracerebral Hemorrhage
SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period.
More
ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score ≥ 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.
More
SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period
More
Intracranial Hemorrhage
The class of Novel Oral Anticoagulants (NOACs) known as direct Factor Xa (FXa) inhibitors has consistently demonstrated comparable or superior efficacy and/or safety relative to its predecessors, Vitamin K Antagonists (VKAs) and Low Molecular Weight Heparins (LMWHs). These agents (apixaban [Eliquis®], betrixaban [BevyxXa®], edoxaban [Savaysa®], rivaroxaban [Xarelto®]) are approved for the prevention of serious thromboembolic outcomes (e.g., stroke, deep vein thrombosis, pulmonary embolism) and have become widely used in the United States (US) and worldwide. One limitation to the use of FXa inhibitors has been the lack of an antidote to be used in cases of severe and/or life-threatening bleeding events. Acute major bleeding occurs at observed rates of 2-4% in pivotal stroke prevention trials in patients with nonvalvular atrial fibrillation [1-3], and such events are often catastrophic. Given the wide adoption and increasing use of FXa inhibitors, the prospect of major bleeding, especially in Intracranial Hemorrhage (ICrH) patients, has become a significant unmet medical need.
More
Intracranial Pressure
Patients who are admitted to the Tufts Medical Center ICU or PICU and are deemed to require placement of an intracranial pressure (ICP) monitor will be asked to enroll in our study. Patients agreeing will undergo the routine placement of an ICP monitor followed by placement of the study device; a non-invasive extracranial device (I PASS - Intracranial Pressure Assessment and Screening System, Vivonics, INC) containing near infrared probes placed on the ear, forehead and finger. The data will be recorded from IPASS as the routine ICP is recorded. Patients vital signs including heart rate, blood pressure, and SpO2 will also be routinely recorded. Once the patient is felt to no longer require the ICP monitor and it is removed, the IPASS device will also be removed.
More
Itching
The purpose of this study is to assess the safety and efficacy of an investigational oral drug called difelikefalin, in reducing the intensity of itching and the impact of itch on your quality of life. The FDA already approved a intravenous(IV) form of the drug to treat moderate-to-severe itchiness in people undergoing hemodialysis. This study continues tests the oral form of the drug in reducing itchiness in people not on dialysis. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill.
More
Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is an exclusion diagnosis that encompasses all forms of otherwise unexplained chronic non-infectious arthritis occurring under the age of 16. Various attempts have been made to classify this heterogeneous group of diseases with the aim of identifying mutually exclusive categories suitable for etiopathogenetic studies. Since then increasing evidence has accumulated suggesting that some of these categories are heterogeneous. Therefore, there is a need to revise the criteria in order to identify more homogeneous entities and to try to distinguish those diseases. The main reason for this research study is to learn more about the diagnosis of Juvenile Idiopathic Arthritis (JIA) according to the ILAR (International League of Associations for Rheumatology) criteria and investigate a new classification criteria proposed by the international research organization Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
More
Keratitis
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.
More
RGN-259 eye drops compared to placebo eye drops 5 times per day in both eyes for the treatment of Neurotrophic Keratopathy. Percentage of subjects achieving complete healing (defined as 0 mm lesion size) of the Persistent Epithelial Defect (PED) at Visit 5 (Day 29) determined by corneal fluorescein staining captured by corneal photography and analyzed by a central reading center
More
Kidney Diseases
The purpose of this study is to assess the safety and efficacy of an investigational oral drug called difelikefalin, in reducing the intensity of itching and the impact of itch on your quality of life. The FDA already approved a intravenous(IV) form of the drug to treat moderate-to-severe itchiness in people undergoing hemodialysis. This study continues tests the oral form of the drug in reducing itchiness in people not on dialysis. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill.
More
We are testing an investigational drug called RGLS8429. “Investigational” means that the study drug being tested is not approved by the United States Food and Drug Administration for use in humans. The main purpose of this study is to get more information about the safety, tolerability (whether side effects can be handled by a subject), pharmacodynamics (how it works on the kidneys), and pharmacokinetics (how the drug is processed in the body) of RGLS8429 in patients with ADPKD. This is a randomized, double blind study, meaning that subjects will be assigned either to the investigational drug or to a placebo. RGLS8429 will be administered by subcutaneous injection (a shot just under the skin) and is being tested in different dose levels.
More
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More
This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
More
The purpose of this trial is to see if the drug ravulizumab is safe and effective in patients with thrombotic microangiopathy (TMA). This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug. You will recieve the drug or placebo for about 6 months and then have follow-up appoinments for about 6 months.
More
Good communication among patients, their families and loved ones, and their medical care providers is important when figuring out how to treat chronic diseases like kidney disease. A lot of people may not know their choices for how to treat kidney disease, and this can lead to rushed decisions or even a sense that there weren't any choices to make. In this study, we are trying to find out if a decision-aid program on a computer can help people with kidney disease have more confidence in their decisions and have better agreement about their decisions with their families and loved ones.
More
The purpose of this clinical trial is to see if the drug Finerenone is safe and effective in patients with in participants with non-diabetic chronic kidney disease. Additionally, while finerenone has been approved for other patient populations, this study will collect additional safety information about finerenone to determine how it affects the body.
More
The purpose of this clincial trial is to see if the drug CSL346 (developed by CSL Behring) is safe and effective in treating type II diabetic kidney disease. We will look at whether the drug decreases the amount of protein in your urine. The drug is given through the vein and under the skin by research nurses under the supervision of the research doctor. This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug.
More
This study looks at whether the drug GFB-887 (developed by Goldfinch Bio) can slow the progression of kidney disease in patients with FSGS and treatment-resistant minimal change disease. The drug works similarly to drugs called calcineurin inhibitors (aka CNIs, such as tacrolimus or cyclosporine) but without some of the side effects those drugs can have. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill. Once you complete this study, you will have the option to enroll in an additional study where all participants receive the drug.
More
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
More
Kidney Transplantation
This study is designed to find out whether there is a difference between how men and women respond to infections or vaccines following heart transplantation. We are recruiting men and women undergoing heart transplantation to participate by providing three blood samples over the course of about six months (taken in the same time and place as usual blood draws used for clinical purposes). We will use these samples to test levels of cells and proteins that are used fight infection and will compare these levels between male and female patients. In addition, we will gather information over the course of the first six post-transplant months about any infections or episodes of heart transplant rejection that you may experience. The point of the study is to identify if there could be different strategies used to prevent or treat infection in male versus female transplant recipients.
More
Laryngoscopy
This study will look at how accurate physician recall is compared to video review for laryngoscopies, which are throat examinations and a standard part of the otolaryngology visit. The hypothesis is that there may be a significant difference in accuracy, creating reason to standardize video recording of the laryngoscopy exam for improved patient outcomes.
More
Leukemia
This randomized phase III trial studies how well imatihib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
More
Liver Diseases
The objectives of this dose escalation study are to confirm the optimal dose of transplanted hepatocytes to safely achieve adequate allogeneic hepatocyte (AH) engraftment into the periduodenal lymph nodes (PDLNs) via endoscopic ultrasound (EUS) in subjects with end-stage liver disease.
More
Patients receiving maintenence hemodialysis will be screened for underlying cognitive impairment using the Montreal Cognitive Assessment (MoCA) Tool, a cognitive screening tool. Routine dialysis data, including biochemical measures and attendance records, will then be subsequently examined. Depending on the MoCA results, patients may be invited to participate in an interview to explore their experience with the MoCA screening tool and other aspects of their dialysis care.
More
Lupus
The purpose of the study is to evaluate the ability and safety of subcutaneous secukinumab 300 mg plus standard of care, compared to placebo plus standard of care, in treating subjects with active Lupus Nephritis.
More
Lupus Erythematosus
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Lyme Disease
Recent studies have shown that the causative agent of Lyme disease, the organism (Borrelia burgdorferi), may persist in animals after antibiotic treatment and can be detected by using natural tick vector (Ixodes scapularis) to acquire the organism through feeding (xenodiagnosis). The aim of this study is to investigate the utility of xenodiagnosis for identifying persistence of infection with B. burgdorferi in treated human Lyme disease.
Our objectives include: (1) assessing the link between the detection of B. burgdorferi by xenodiagnosis and the persistence of symptoms in patients diagnosed with Lyme disease, (2) comparing the rate of detection of B. burgdorferi by xenodiagnosis after therapy in participants with posttreatment Lyme disease symptoms, (3) identifying subject characteristics related to the likelihood of detecting B. burgdorferi by xenodiagnosis, and (4) continuing to evaluate the safety of xenodiagnosis in humans.
More
Lymphomas
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).
Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread.
Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab.
Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
More
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose.
More
The study will enroll approximately 380 participants with aggressive B-cell malignancies and indolent B-cell malignancies.
More
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
More
The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) or R/R follicular lymphoma (FL). Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R FL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab.
More
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
More
Macular Degeneration
This study is a Phase IV multicenter, open-label (BCVA assessor-masked) study designed to assess the response to treatment with SUSVIMO every 24 weeks in patients with Neovascular Age-Related Macular Degeneration (nAMD) who have been previously treated with anti-VEGF agents other than ranibizumab.
More
This is a longitudinal observational study that will look at 300 subjects, 200 with intermediate AMD in at least one eye, or with AMD in one eye, either early or intermediate, and with late AMD (exudative) in the other eye, and 100 subjects with nGA or GA in at least one eye.
The target population is all subjects who are at least 50 years of age and have a clinical diagnosis of non-exudative AMD in at least one eye.
Subjects who convert to exudative AMD during the study will be treated as per the enrolling physician’s standard of care and will continue to be scanned per protocol, allowing for a wider interval of +/- 30 days around the standard timing of scanning to avoid excessively frequent visits.
More
Macular Edema
This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab compared with aflibercept in patients with macular edema due to branch retinal vein occlusion (BRVO) up to the primary endpoint at Week 24.
More
Melanoma
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that has spread to other places in the body (advanced). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine how quickly patients can be divided into groups based on biomarkers in their tumors. A biomarker is a biological molecule found in the blood, other body fluids, or in tissues that is a sign of a normal or abnormal process or a sign of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. The two biomarkers that this trial is studying are "tumor mutational burden" and "tumor inflammation signature." Another purpose of this trial is to help doctors learn if cabozantinib and nivolumab shrink or stabilize the cancer, and whether patients respond differently to the combination depending on the status of the biomarkers.
More
Menstruation
This is a research study to find out more about preterm labor and preeclampsia during pregnancy. We would like to study the uterine lining and monthly cycles to find out if they have any role to play in preterm labor or preeclampsia.
More
Mental Disorders
This research study is a 3-week clinical trial of dronabinol, a synthetic form of tetrahydrocannabinol (THC). This study is being done to determine if dronabinol is a safe and effective treatment for agitation symptoms related to Alzheimer’s disease. This study will compare dronabinol to a placebo.
More
Migraine
The purpose of this study is to collect information about treatment patterns, effects, and outcomes in patients with migraines who are switching or initiating a pharmacologic treatment for migraine prevention. This is an observational study which means there will be no treatment added or taken away.
More
Mouth Disorders
We are doing a research study to test a technology called spectroscopy that uses a special light and computer to better “see” where cancer is during surgery. We want to see if it can make surgery for mouth and throat cancer more effective by letting the doctor know if there are any cancer cells left behind during surgery.
More
Multinodular Goiter
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab-daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd). Teclistamab is an new drug that is being evaluated to treat participants with multiple myeloma, an incurable malignant plasma cell disorder. This is a multicenter, randomized, open-label, Phase 3 study in multiple myeloma patients who have previously received 1 to 3 prior line(s) of therapy including a PI and lenalidomide.
More
The purpose of this study is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and efficacy of different doses of elranatamab, as well as different intervals between doses.
More
In response to the significant need to intensify efforts at early diagnosis, this trial proposes further building on knowledge of the genetic basis of AL in clonal plasma cells. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease.
More
Multiple Sclerosis
The purpose of the study is to assess the efficacy and safety of SAR442168 compared with teriflunomide (Aubagio) in participants with relapsing multiple sclerosis (RMS).
The experimental drug works in the blood and in the brain where it blocks a molecule called “Bruton's tyrosine kinase (BTK)”, which is present in some cells involved in multiple sclerosis (immune cells known as B-cells and microglial cells). This mechanism of action may help stop the formation of new brain lesions in MS.
More
The purpose of the study is to see if the study drug, SAR442168, works to delay the progression of disability in people with NRSPMS compared to placebo and has an acceptable safety profile.
More
The purpose of the study is to see if the study drug, SAR442168, works to delay the progression of disability in people with PPMS compared to placebo and has an acceptable safety profile.
More
To demonstrate that remibrutinib is superior to teriflunomide in reducing the frequency of confirmed relapses.
More
This study focuses on developing a new portable noninvasive system to aid in the diagnosis of the vision disorders Multiple Sclerosis and Optic Neuritis. This device combines images and patterns using a Head Mounted Display, similar to a virtual reality headset. The system measures brain responses to these images using a form of electroencephalography (EEG), which will give us information about how the brain and eyes communicate and how this may be affected by a vision disorder.
More
Muscle Disorders
Evaluate the correlation between ICU Skeletal muscle loss and protein intake and investigate the lack of daily protein intake by the presence of loss of rectus femoris muscle quantity and quality.
More
Myasthenia Gravis
This is a phase 3, randomized, double-blind, placebo-controlled, multicenter study that evaluates using ravulizumab infusions as treatment for patients with generalized Myasthenia Gravis. Participants will receive either ravulizumab for the duration of the study or placebo during the 26-week randomized-controlled period of the stufy and then enter the open-label extension period where they will receive ravulizumab. The main outcome will look at the change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at week 26 (end of randomized period).
More
Mycobacterial Disease
This study is being conducted in patients with refractory Mycobacterium Avium Complex (MAC), a serious condition which can cause damage to your lung, and is resistant to other treatments. The study is looking at how effective the study drug, Epetraborole in the treatment of refractory MAC. Epetrabole is a oral pill to be taken as 2 tablets one time daily by mouth. Details of study visits are explained below.
More
Myeloma
The drug being tested in this study is called modakafusp alfa (TAK-573). Modakafusp alfa is being tested to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy in combination with daratumumab in participants with relapsed or refractory multiple myeloma (RRMM).
More
Myocardial Heart Disease
The MADIT S-ICD trial is designed to evaluate if subjects with a prior myocardial infarction, diabetes mellitus and a relatively preserved ejection fraction of 36-50% will have a survival benefit from receiving a subcutaneous implantable cardioverter defibrillator (S-ICD) when compared to those receiving conventional medical therapy.
More
Myopia
This study will last approximately 4 years. Screening will last for approximately 2 weeks. Stage 1, where subjects will be randomized in a 2:1 ratio to OT-101 Ophthalmic Solution or placebo, will last approximately 3 years. Stage 2, where subjects previously assigned to OT-101 Ophthalmic Solution will be re-randomized to either continue with OT-101 Ophthalmic Solution or switch to placebo and subjects previously assigned to placebo will continue with placebo, will last approximately 1 year. Subjects will be asked to undergo visual acuity testing and intraocular examinations at visits every 6 months. Ocular imaging will be performed on a yearly basis.
More
Nasal Polyps
The aim of this study is to investigate the use of benralizumab in patients with eosinophilic CRSwNP, and comorbid asthma, whose severity is consistent with a need for surgery despite ongoing treatment with intranasal corticosteroids and a history of treatment with systemic corticosteroids or prior surgery for CRSwNP. The effect of benralizumab 30 mg on nasal polyps will be assessed on top of standard of care therapy with INCS over a 56-week treatment period.
More
Neonatal Necrotizing Enterocolitis
We will collect salivary and stool samples from newborns born in our NICU and obtain mRNA sequencing to identify microbial colonization. We will attempt to correlate aberrant colonization with adverse outcomes of newborn mortality and morbidities such as NEC and sepsis.
More
Neonatal Abstinence Syndrome
This pilot study is aimed at furthering our understanding of prototypical feeding behaviors in newborns born to mothers who used opiates and/or cannabinoids during pregnancy. It is well known that infants born drug-exposed may struggle with their oral feeding skills or may consume 20-40% more calories per day than infants who were not drug exposed during gestation. Our understanding of the molecular mechanisms involved in these feeding behaviors is poorly understood. By comparing the salivary expression of key hypothalamic regulatory genes and/or proteins known to be assoicated with feeding and reward behaviors between drug and non-drug exposed newborns, we hoped to elucidate biological mechanisms responsible for aberrent feeding behaviors.
More
Neonatal Care
Low IGF-1 levels in extremely preterm infants (gestational age [GA] of 23 weeks +0 days to 27 weeks +6 days) are a risk factor for CLD and other complications of extreme prematurity. An increase of serum IGF-1 levels provided by SHP607 administration may reduce the incidence of CLD and other complications of extreme prematurity. This would be the only available preventive pharmacological therapy leading to an absolute decrease in the incidence of moderate or severe BPD and an absolute decrease in the incidence of IVH for extremely premature babies translating to an improvement in long-term pulmonary and neurodevelopmental outcomes which are key drivers for short- and long-term use of resources. Subjects will be randomly assigned on a per site basis to treatment either with SHP607 (250 μg/kg/24 hours or 400 μg/kg/24 hours) or to receive standard neonatal care in a 1:1:1 ratio. Standard neonatal care is determined based upon the individual premature infant’s condition and clinical judgment of the treating physician and may include interventions for thermoregulation, blood pressure support, respiratory/ventilatory support, nutritional support, treatment for infections, etc. Recognizing that medical care required for each premature infant may vary, other than those specific parameters outlined in the protocol, local neonatal intensive care unit (NICU) practices and investigator’s judgment for care decisions are to be followed. Subjects randomly assigned to treatment with SHP607 will receive continuous IV infusion of study drug commencing within 24 hours of birth, once all baseline assessments have been completed. The infusion of study drug will continue to PMA 29 weeks +6 days, when the subjects’ endogenous production of IGF-1 is considered sufficient to maintain physiologic serum IGF-1 levels for corresponding GA. Infusion of study drug may be discontinued before PMA 29 weeks +6 days if IV access is not possible according to the clinical judgment of the investigator or when the responsible physician, for other medical reasons, decides that infusion of study drug should be discontinued. Initially, enrollment will be restricted to subjects of GA ≥26 weeks (26 weeks +0 days to 27 weeks +6 days). After approximately 75 subjects (approximately 25 subjects in each treatment group) have completed the PMA 40 weeks visit, the DMC will assess safety and preliminary efficacy data, where preliminary efficacy assessments would include review of imbalances in BPD and IVH incidence between study groups. Based on the outcomes of these assessments, the DMC may authorize enrollment of subjects of GA between 23 weeks +0 days and 27 weeks +6
More
This is a prospective, multi-center clinical study to validate the effectiveness of the Boppli Blood Pressure Monitor as compared to an invasive arterial reference. This study will evaluate the accuracy and precision of the Boppli system for continuous blood pressure monitoring by comparing SBP, DBP, and MAP against the reference methodology in pediatric and neonatal populations.
Primary Effectiveness Endpoint: Mean and standard deviation of the difference of the paired measurements between the device and arterial line reference for systolic, diastolic and mean pressures treated separately.
Safety endpoint: Device related adverse events
To assess the accuracy of the test device, a mean average difference of +/- 5 mmHg with a standard deviation of 8 mmHg of difference between the test device and the intra-arterial reference method will be considered as the upper limits of clinically acceptable disagreement. These parameters are in accordance with ISO 81060-2 and ANSI/AAMI SP10 for neonatal/infant populations using an intra-arterial method as the reference standard.
In addition to the test of accuracy, the stability test will be used to assess the accuracy over the duration of use of the device.
The change test will be used to demonstrate that the Boppli device will measure clinically relevant changes in BP measurements.
More
Neonatal Opioid Withdrawal Syndrome
This pilot study is aimed at furthering our understanding of prototypical feeding behaviors in newborns born to mothers who used opiates and/or cannabinoids during pregnancy. It is well known that infants born drug-exposed may struggle with their oral feeding skills or may consume 20-40% more calories per day than infants who were not drug exposed during gestation. Our understanding of the molecular mechanisms involved in these feeding behaviors is poorly understood. By comparing the salivary expression of key hypothalamic regulatory genes and/or proteins known to be assoicated with feeding and reward behaviors between drug and non-drug exposed newborns, we hoped to elucidate biological mechanisms responsible for aberrent feeding behaviors.
More
Neonatal Sepsis
We will collect salivary and stool samples from newborns born in our NICU and obtain mRNA sequencing to identify microbial colonization. We will attempt to correlate aberrant colonization with adverse outcomes of newborn mortality and morbidities such as NEC and sepsis.
More
Nephropathy
Additional development of an enzyme called IgA protease as a means to remove IgA (a protein) from the kidney.
More
ARTEMIS – IGaN is a maximum 160 week a Phase 3 trial evaluating the Safety and Efficacy of OMS721 in patients with Immunoglobulin A (IgA) Nephropathy
More
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
More
This study looks at whether the drug GFB-887 (developed by Goldfinch Bio) can slow the progression of kidney disease in patients with FSGS and treatment-resistant minimal change disease. The drug works similarly to drugs called calcineurin inhibitors (aka CNIs, such as tacrolimus or cyclosporine) but without some of the side effects those drugs can have. This study is double blind and placebo controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a fake pill. Once you complete this study, you will have the option to enroll in an additional study where all participants receive the drug.
More
Neuroblastoma
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
More
Neurologic Diseases
This study is evaluating the potential to use transcranial magnetic stimulation in diagnosis of diagnosis of neurologic conditions that effect movement. We are seeking healthy volunteers and participants with a neurologic condition that affects the ability to move parts of your body.
More
Neurotrophic Keratitis
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.
More
After completing enrollment in the original DEFENDO Study, patients will be invited to enter the DEFENDO Long-Term Follow-up Study (all standard of care is permitted). Two additional long-term follow-up visits will occur at 18- and 24-months to evaluate long-term clinical outcomes. No study treatment will be provided. Patients will be treated per standard of care as determined by the Investigator and will document topical ophthalmic medications currently being administered at time of study participation.
More
Non-Alcoholic steatohepatitis
You are being invited to consider participation in a clinical research study for patients with cirrhosis caused by nonalcoholic steatohepatitis (NASH) This study involves research and is conducted to determine the safety and efficacy of a new investigational drug called aldafermin (previously known as NGM282
More
The purpose of this study is to find out about the safety and efficacy of VK2809 for the treatment of non-alcoholic steatohepatitis (NASH).
More
Non-Hodgkin Lymphoma
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile.
More
Obesity
Obesity is a chronic, debilitating, multi-factorial disease that has reached worldwide pandemic proportions. The prevalence of obesity has tripled since the 1980s in many countries of the World Health Organization (WHO) European region. The WHO estimates that by 2015, 2.3 billion people will be overweight and over 700 million will be obese. Furthermore, the movement of people into the obese category (Body Mass Index (BMI) > 30) continues to increase by 1% of the population per year2, and the prevalence of the Class III obesity has almost doubled over the last twenty years with an estimated prevalence of 4.7% in 1999-2000 and 9.2% in 2017-2018%.Significant evidence indicates that successful treatment of obesity results in a reduced incidence of co-morbid diseases. Specifically, a 5-10% total weight loss can significantly reduce or prevent coronary heart disease, hyperlipidemia, hypertension, type 2 diabetes, and other chronic diseases in obese individuals. A combination of calorie restricted diet, regular physical activity, and behavioral modification with or without pharmacotherapy has been utilized to treat obesity; however, a significant weight loss of 10 to 15% is rarely achieved or sustained9. For morbid obesity, bariatric surgery is the only treatment option with sustainable weight loss. However, some patients with moderately increased BMI do not qualify for bariatric surgery or prefer less invasive treatment modalities. In these patients, an intragastric balloon (IGB) can help them adhere to lifestyle modification, preventing the need for bariatric surgery. IGB treatment, in addition to lifestyle modification, has been shown to be an effective short-term modality for weight loss.
More
We're doing a study to see how belly fat affects blood vessels in men and women. We want to find out if there are any differences and how this affects heart health. This will help us come up with better ways to prevent and treat heart disease.
More
The aim of this study is to improve the metabolic health of overweight and obese women prior to a planned pregnancy.
More
Ophthalmology
Patient who need vision testing ( acuity and fields) will be asked to be tested at home or at the bedside with the ViuALL device. They and their physicians will be asked about the advantages and disadvantages of the new device.
More
The study is being conducted to compare whether an optical correction of bifocal spectacle lenses (BFL) or single-vision spectacle lenses (SVL) is more effective for the treatment of children with esotropia greater at near. Children will be randomized to be treated with BFLs or SVLs for 3 years and be evaluated at regular intervals throughout the study to determine whether their condition has worsened. Children whose condition worsens during the study will either start BFL treatment (if randomized to SVL group) or continue BFL treatment (if randomized to BFL group) for 2 months to allow assessment of outcome in BFLs, and then be released to treatment at investigator discretion while continuing in study follow-up. Children whose condition has not worsened during the study will start or continue BFL (depending on treatment group) for 2 months at 3 years. All children return at 38 months to assess binocular function. The effectiveness and safety of both treatments will be compared.
More
Optic Neuritis
This study focuses on developing a new portable noninvasive system to aid in the diagnosis of the vision disorders Multiple Sclerosis and Optic Neuritis. This device combines images and patterns using a Head Mounted Display, similar to a virtual reality headset. The system measures brain responses to these images using a form of electroencephalography (EEG), which will give us information about how the brain and eyes communicate and how this may be affected by a vision disorder.
More
Oropharyngeal Cancer
This study is being done to answer the following question:
Does maintenance nivolumab following definitive therapy with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer (intermediate risk HPV positive oropharynx cancer).
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your HPV positive oropharynx cancer. The usual approach is defined as care most people get for HPV positive oropharynx cancer.
More
Orthopaedic Surgery
The purpose of this study is to establish a large, international, web based registry, using the Surgical Outcomes System (SOS), to collect baseline characteristics of patients undergoing orthopaedic and sports medicine, arthroscopy, and related surgery, and the subsequent outcomes and costs-effectiveness associated with the surgical procedures. Additionally, baseline and outcome data for non-operative treatment procedures will b collected using the same measures in order to compare to surgical outcomes.
Health care providers participate in the SOS registry for the primary purpose of tracking their patient's outcomes and evaluating the global outcomes of various standard of care orthopaedic and sports medicine medical procedures, in order to develop evidence based protocols fo the best methods for treating patients with different conditions. The sponsor, Arthrex, uses the protected health information submitted from the health care providers to create aggregated healthcare provider and de-identified global averages. The de-identified global data is shared with all participants. Healthcare providers use this information to perform healthcare operations including outcomes evaluation and development of clinical guidelines. The aggregated data provide orthopaedic and sport medicine healthcare providers' feedback on their patient's outcomes relative to global benchmarks.
Secondarily, healthcare providers participate in the SOS registry for the purposes of analyzing and publishing outcomes of specific standards of care procedures, techniques, devices/biologics (i.e."research"), as well as to utilize the de-identified data for patient education of expected outcomes and to provide evidence of successful surgical/treatment outcomes to their peers and future patients. Except for technical and system functionality purposes (for example, registry maintenance, data aggregation, and de-identification), the sponsor only views and uses the global de-identified global dataset. Arthrex uses the global de-identified data for the purposes of international product approval, internal research and product develop, and marketing. healthcare providers participating in the SOS registry for primary and secondary research purposes are designated as study doctors in this protocol.
Only data associated with labeled indications of approved or cleared orthopedic devices and/or biologics are intended to be collected. Data will be collected from the subject and study doctor, who is the same person as the subjection's treating physician, by completing data fields and surveys on a web based secure site, which is maintained by the sponsor. From the information collected and analyzed in this study the study doctors and study sponsor hope to learn more about the cost-effectiveness of surgical and non-operative interventions and subjects' pain, function and well-being before and after treatment. The sponsor, Arthrex Inc., manufactures medical devices for orthopedic sports medicine and arthroscopy that may be used in the subjects' surgery. Arthrex does not participate in the study doctor's selection or provision of treatment for any specific subject, including the selection medical device.
More
Osteoarthritis
This study aims to provide crucial knowledge about the neurobiological mechanisms underlying mind-body therapy for knee osteoarthritis (OA). We will investigate the central mechanism of knee OA pain using brain imaging technology to evaluate how brain function and structure change in response to mind-body exercise over time.
Participants will be randomized to either a Tai Chi or Wellness Education class and asked to come to Tufts Medical Center twice a week for 12 weeks, along with a baseline and follow-up visit (26 study visits). The findings will lead to the establishment of a new treatment paradigm in OA and have broad application to the management of chronic musculoskeletal pain.
More
This study will evaluate the potential usefulness and effectiveness of Virtual Reality (VR) in reducing pain for adults with chronic knee osteoarthritis (OA).
More
The purpose of the study is to evaluate for long term changes in pain and function in knee osteoarthritis and also to ascertain differences in health care utilization among subjects who participated in the randomized controlled trial on effect of intra-articular steroids on structural progression of knee osteoarthritis (IACS)
More
The purpose of this clinical research study is to learn more about the use of the study drug, amnion suspension allograft (written as ‘ASA’ in this form), for the potential treatment of osteoarthritis (OA) of the knee. The ASA injection is being studied to see if it improves the knee pain and function in people with knee OA
More
This study evaluates the efficacy and safety of fasinumab compared to placebo, diclofenac, and celecoxib (diclofenac and celecoxib are standard-of-care non-steroidal anti- inflammatory drugs, NSAIDs, used for moderate-to-severe pain due to OA). The study drug will be administered for up to 24 weeks in patients with OA of the knee or hip. Fasinumab aims to selectively block nerve growth factor (NGF), a protein that causes pain. Blocking NGF may reduce pain due to OA of the hip and knee. Fasinumab is being test and is not approved for use in pain management by the United States Food and Drug Administration (FDA).
More
This is a clinical study that explores the effects of Tai Chi or Wellness Education on the gut bacteria of patients with Osteoarthritis. Our intervention is aimed at decreasing pain and improving quality of life for osteoarthritis patients.
To measure bacterial changes, participants stool samples will be collected and analyzed.These results will help determine mechanisms between bacteria, pain and behavioral pathways as well as progress future research to the potential disease-modifying role of mind-body approaches.
More
You are invited to take part in an assessment of MRI (Magnetic Resonance Imaging) equipment. The MRI examination will be one study visit that will take place at Tufts Medical Center and will take up to 1 hour. It is important to be aware that the images will only be analyzed for evaluating the quality of the images. The images will not be evaluated for any diseases.
More
Pancreatic Cancer
The purpose of this study is to compare the usual treatment approach (surgery followed by chemotherapy) to using chemotherapy followed by surgery and then more chemotherapy
More
Peritoneal Cancer
PICCOLO is a Phase 2, multicenter, open label study designed to evaluate the safety and efficacy of MIRV in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression. Mirvetuximab Soravtansine (MIRV) is an investigational drug designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to the tumor cells carrying a tumor-associated protein called folate receptor alpha (FRα). It is being developed for the treatment of subjects with recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
More
Polycystic Kidney Disease
This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD.
The primary objectives of this study is assess the off-treatment change from baseline in estimated glomerular filtration rate (eGFR) at Week 52 or following a 4-week drug treatment withdrawal period in the first year of treatment and to assess safety and tolerability.
More
To provide continuing open-label treatment with bardoxolone methyl as part of this extended access program while collecting ongoing safety and tolerability data of bardoxolone methyl.
More
Post-Operative Pain
The purpose of this research is to find out if a local administration of liposomal bupivacaine works as well, or better, than our standard of care medication solution when administered in the same way to manage pain after surgery.
More
Preeclampsia
This is a research study to find out more about preterm labor and preeclampsia during pregnancy. We would like to study the uterine lining and monthly cycles to find out if they have any role to play in preterm labor or preeclampsia.
More
Understanding the etiology of preeclampsia and spontaneous preterm delivery through the characterization of placental trophoblasts and maternal decidual leukocytes as well as their interactions
More
Pregnancy
This study assesses if it is possible to provide produce as a prescription in prenatal clinical care for pregnant women and to understand the impact that may have on their health and the health of their newborns after delivery.
More
The FEED study will focus on maternal feeding styles and practices. Feeding styles refers to the attitudes, emotional climate, and quality of the interaction that parents maintain with their child during feeding. Feeding practices refer to specific strategies that parents use to feed their children. Research studies have shown that feeding styles and practices can interact to influence a child’s food preferences, dietary intake and weight status. Less is known about how feeding styles and practices track in early life. This research study will investigate these relationships and look at the relationship between feeding and infant adiposity.
More
GO MOMS is a study that tracks maternal blood sugar levels in pregnancy and how the levels may predict the development of gestational diabetes (pregnancy-related high blood sugar) or relate to the size of a baby at birth. As not enough is known about who will get gestational diabetes and because treatment of gestational diabetes in later pregnancy does not make all of the complications go away, learning about the early pregnancy blood sugars may help us learn how to improve prenatal care in the future for healthier families.
More
The purpose of the study is to measure the softness of the cervix. The softness of the cervix will be compared in two groups of pregnant women. One group is women who will be having a surgery to strengthen the cervix (a cerclage surgery). The second group is normal women in the prenatal clinic. We anticipate recruiting 140 patients total (60 cases and 80 control patients.)
More
This is a research study to find out more about preterm labor and preeclampsia during pregnancy. We would like to study the uterine lining and monthly cycles to find out if they have any role to play in preterm labor or preeclampsia.
More
The aim of this study is to improve the metabolic health of overweight and obese women prior to a planned pregnancy.
More
The purpose of this study is to measure the effect of maternal metabolism (how your body uses food for energy) on the growth of the placenta (afterbirth), and how the placenta uses lipids.
More
The purpose of this study is to measure the effect of maternal diet and metabolism (how your body uses food for energy) on the growth of the baby, and how the placenta uses lipids.
More
This study will determine how the placenta is affected by glucose in early pregnancy.
More
Premature Babies
Premature infants can get a serious inflammatory condition, called necrotizing enterocolitis (NEC), that damages parts of the intestines. It is the most common cause of illness of the intestinal tract in premature infants in the first few weeks of life. It is a very serious condition that can lead to death in up to half of affected infants. There is no way to predict whether an infant will get NEC, and there are no reliable early warning signals. There is no established preventive treatment for NEC. Infants with NEC are usually treated with bowel rest (stopping feeding by mouth), antibiotic medicines, and in some cases with surgery where the affected bowel needs to be removed.
Some studies have shown that live bacteria given to the intestine of premature infants as early as possible in their life might be able to prevent NEC. Researchers want to find out if an investigational drug called “IBP-9414”, which is made of living bacteria, can help prevent NEC in prematurely born infants. An investigational drug is a drug that is being tested and is not approved for use and sale by any authorities (like the U.S Food and Drug Administration [FDA], the European Medicines Agency [EMA], or the authority in your country
All infants in the study will receive “standard-of-care” treatment, which means they will receive the same medical treatment they would receive if they were not in the study. In addition to the standard-of-care treatment that all infants will receive, half of the infants in the study will receive the investigational drug (IBP-9414) and half will receive an inactive substance (contains no medicine) called “placebo”. Receiving placebo is the same as not receiving any medication other than the standard-of-care treatment. The reason placebo is used in this study is to help the researchers know if any effects they see in the study are because of the investigational drug rather than the researchers’ expectations about the effects of the study drug. Neither you nor the study doctor/staff will be able to choose or to know whether your child receives IBP 9414 or placebo. This is why the study is called “double blind”. Your child will be assigned at random (like flipping a coin) to receive IBP 9414 or placebo. Your child’s chances of receiving IBP 9414 or placebo are the same (50 50 chance). In case of medical need, the study doctor will be able to find out whether your child is receiving IBP 9414 or placebo. In this study, the placebo will be sterile water. Please ask the study doctor or study staff if you have any questions about your child receiving placebo.
The main purpose of this study is to see if IBP-9414 can prevent NEC and if it is safe and tolerable. The unit that doses of live bacterial drugs are measured in is called “colony forming units” or CFUs. The dose of IBP-9414 to be tested is 1x109 CFU, which means it contains 1 billion live bacteria. This dose has been tested previously in a smaller study of IBP-9414 and was found to be safe and tolerable. In order to see if this dose actually can prevent NEC, a much larger study involving more infants is needed.
It is planned that 2158 premature infants will be included in this study, who will be less than 48 hours old at the time they begin taking part. At the end of the study, the researchers will compare the infants who received IBP 9414 with those who received placebo, to help decide if receiving IBP 9414 can prevent NEC and if it is safe for premature infants.
While the study doctor responsible for your child will monitor the safety of your individual infant, the safety of all infants in the study, as well as the effect of IBP 9414, will also be monitored on an ongoing basis throughout the study by a so-called Data Monitoring Committee (DMC). A DMC is a panel of experts who are independent from the study team and the pharmaceutical company developing IBP 9414.
Most of the infants (1942) in the study will weigh up to 1000 grams birth weight (about 2 lbs) and the rest (216) will weigh 1001 to 1500 grams (about 2 lbs to about 3 lbs).
The study will start with a group of 300 infants, all of whom will be in the intermediate weight category (750-1000 grams category). After 300 infants have completed treatment, a panel of experts (called a Data Monitoring Committee or DMC), who know which treatment each infant received, will determine if IBP-9414 appears to be safe and well tolerated. Enrollment in the study will continue during this review.
Based on the DMC recommendation, enrollment will open to infants from the lower weight category (500 749 grams), alongside the intermediate weight category (750 1000 grams).
A second DMC safety review will occur after the first 600 infants have completed treatment. Enrollment in the study will continue during this review.
A third DMC safety review will be performed after 1400 infants have completed treatment. Enrollment in the study will continue during this review.
After 1400 infants, the plan is to open recruitment to infants in the higher birth weight category (1001 1500 grams). The study will continue with all 3 birth weight categories until 2158 infants have been enrolled
More
The purpose of this study is to study environmental risk factors and epigenetic processes as potential contributors to neurodevelopmental impairments in a group of individuals at very high risk by focusing on the relationship of prenatal exposure to placental inflammation markers and neonatal inflammation markers, the relationship of these inflammation markers to functional neuodevelopmental disorders and on the relationship of these markers to brain structural abnormalities.
More
Premature Birth
Premature infants can get a serious inflammatory condition, called necrotizing enterocolitis (NEC), that damages parts of the intestines. It is the most common cause of illness of the intestinal tract in premature infants in the first few weeks of life. It is a very serious condition that can lead to death in up to half of affected infants. There is no way to predict whether an infant will get NEC, and there are no reliable early warning signals. There is no established preventive treatment for NEC. Infants with NEC are usually treated with bowel rest (stopping feeding by mouth), antibiotic medicines, and in some cases with surgery where the affected bowel needs to be removed.
Some studies have shown that live bacteria given to the intestine of premature infants as early as possible in their life might be able to prevent NEC. Researchers want to find out if an investigational drug called “IBP-9414”, which is made of living bacteria, can help prevent NEC in prematurely born infants. An investigational drug is a drug that is being tested and is not approved for use and sale by any authorities (like the U.S Food and Drug Administration [FDA], the European Medicines Agency [EMA], or the authority in your country
All infants in the study will receive “standard-of-care” treatment, which means they will receive the same medical treatment they would receive if they were not in the study. In addition to the standard-of-care treatment that all infants will receive, half of the infants in the study will receive the investigational drug (IBP-9414) and half will receive an inactive substance (contains no medicine) called “placebo”. Receiving placebo is the same as not receiving any medication other than the standard-of-care treatment. The reason placebo is used in this study is to help the researchers know if any effects they see in the study are because of the investigational drug rather than the researchers’ expectations about the effects of the study drug. Neither you nor the study doctor/staff will be able to choose or to know whether your child receives IBP 9414 or placebo. This is why the study is called “double blind”. Your child will be assigned at random (like flipping a coin) to receive IBP 9414 or placebo. Your child’s chances of receiving IBP 9414 or placebo are the same (50 50 chance). In case of medical need, the study doctor will be able to find out whether your child is receiving IBP 9414 or placebo. In this study, the placebo will be sterile water. Please ask the study doctor or study staff if you have any questions about your child receiving placebo.
The main purpose of this study is to see if IBP-9414 can prevent NEC and if it is safe and tolerable. The unit that doses of live bacterial drugs are measured in is called “colony forming units” or CFUs. The dose of IBP-9414 to be tested is 1x109 CFU, which means it contains 1 billion live bacteria. This dose has been tested previously in a smaller study of IBP-9414 and was found to be safe and tolerable. In order to see if this dose actually can prevent NEC, a much larger study involving more infants is needed.
It is planned that 2158 premature infants will be included in this study, who will be less than 48 hours old at the time they begin taking part. At the end of the study, the researchers will compare the infants who received IBP 9414 with those who received placebo, to help decide if receiving IBP 9414 can prevent NEC and if it is safe for premature infants.
While the study doctor responsible for your child will monitor the safety of your individual infant, the safety of all infants in the study, as well as the effect of IBP 9414, will also be monitored on an ongoing basis throughout the study by a so-called Data Monitoring Committee (DMC). A DMC is a panel of experts who are independent from the study team and the pharmaceutical company developing IBP 9414.
Most of the infants (1942) in the study will weigh up to 1000 grams birth weight (about 2 lbs) and the rest (216) will weigh 1001 to 1500 grams (about 2 lbs to about 3 lbs).
The study will start with a group of 300 infants, all of whom will be in the intermediate weight category (750-1000 grams category). After 300 infants have completed treatment, a panel of experts (called a Data Monitoring Committee or DMC), who know which treatment each infant received, will determine if IBP-9414 appears to be safe and well tolerated. Enrollment in the study will continue during this review.
Based on the DMC recommendation, enrollment will open to infants from the lower weight category (500 749 grams), alongside the intermediate weight category (750 1000 grams).
A second DMC safety review will occur after the first 600 infants have completed treatment. Enrollment in the study will continue during this review.
A third DMC safety review will be performed after 1400 infants have completed treatment. Enrollment in the study will continue during this review.
After 1400 infants, the plan is to open recruitment to infants in the higher birth weight category (1001 1500 grams). The study will continue with all 3 birth weight categories until 2158 infants have been enrolled
More
The purpose of this study is to study environmental risk factors and epigenetic processes as potential contributors to neurodevelopmental impairments in a group of individuals at very high risk by focusing on the relationship of prenatal exposure to placental inflammation markers and neonatal inflammation markers, the relationship of these inflammation markers to functional neuodevelopmental disorders and on the relationship of these markers to brain structural abnormalities.
More
This study is being conducted to find out what genes are turned on or off (called "gene expression") in babies born preterm and how that may be related to complications of prematurity or other health conditions they may experience during or after their initial hospitalizations.
More
Pressure Ulcers
llion people per year and costs over $26 billion (1-11). Pressure Ulcer (PU) is major disease burden to the US military and civilian populations and identifying new treatments for PUs is a priority for DoD (1-11). Despite significant advances in the development of gene and protein therapy and tissue-engineered skin substitutes to treat pressure ulcers (PUs), inability to achieve complete healing of PUs in advanced stages (Stage-3 and Stage-4) when bone and muscle are damaged in addition to skin in the PU, and prevent PU recurrence, remain the greatest challenge for physicians and patients (1-11). Thus, the overarching goal of this DoD-funded project is to develop a new deep tissue treatment that delivers nucleic acid and protein therapeutics directly to deep tissues in the wound bed of pressure ulcers (PUs) within seconds to activate deep tissue repair. We expect that such a treatment will achieve complete healing of advanced PUs (Stages 3 and 4), prevent PU recurrence, and improve patient outcomes.
More
Preterm Birth
This is a research study to find out more about preterm labor and preeclampsia during pregnancy. We would like to study the uterine lining and monthly cycles to find out if they have any role to play in preterm labor or preeclampsia.
More
Understanding the etiology of preeclampsia and spontaneous preterm delivery through the characterization of placental trophoblasts and maternal decidual leukocytes as well as their interactions
More
Primary Sclerosing Cholangitis
The purpose of this study is to create a research tissue bank to collect, process, and store samples until researchers need them to do research. Tissue samples in this bank will be used mainly for research on primary sclerosing cholangitis (PSC). You have been asked to take part of this study because you have PSC, another related disease, or are a healthy person.
More
Proteinuria
The purpose of this phase 3 trial is to see if the drug Sibeprenlimab is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine and delay kidney disease progression. If you qualify, you will receive either Sibeprenlimab or placebo for 100 weeks. We will then follow up with you for 8 weeks after after the final study drug treatment.
More
The purpose of this Phase II trial is to see if R3R01 is safe in patients with Alport Syndrome and Focal Segmental Glomerulosclerosis. This will be done by evaluating how efficient R3R01 is in decreasing proteinuria levels. The study will consists of a screening period, a treatment period, and a follow-up period. If you qualify, you will receive the study drug R3R01 for 12 weeks. We will then follow up with you after for an additional 12 weeks.
More
This is a study of the prevalence of APOL1 alleles in adults who are of recent African ancestry or geographic origin. The study will enroll up to a total of approximately 2500 subjects into 2 groups. Group 1 includes subjects with FSGS, and Group 2 includes subjects with other forms of proteinuric nondiabetic CKD. No study drug will be administered.
More
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
More
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN, FSGS, DKD, and Alport Syndrome.
The study is comprised of an optional pre-screening period, screening, treatment, and follow-up periods. If you qualify, you will receive the study drug Atrasentan for up to 1 year.
More
The purpose of this clinical trial is to see if the drug atrasentan is safe and effective in treating IgAN. We will look at whether the drug decreases the protein levels in your urine.
The study is comprised of an optional pre-screening period, a screening period, a treatment period and a follow-up period. If you qualify, you will receive either the study drug Atrasenten or placebo for up to 2.5 years.
More
The purpose of this clinical trial is to see if the drug Finerenone is safe and effective in patients with in participants with non-diabetic chronic kidney disease. Additionally, while finerenone has been approved for other patient populations, this study will collect additional safety information about finerenone to determine how it affects the body.
More
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
More
Psychotic Disorders
This research study is a 3-week clinical trial of dronabinol, a synthetic form of tetrahydrocannabinol (THC). This study is being done to determine if dronabinol is a safe and effective treatment for agitation symptoms related to Alzheimer’s disease. This study will compare dronabinol to a placebo.
More
Pulmonary Fibrosis
The primary objective of the study is to evaluate the safety and efficacy of inhaled treprostinil in subjects with IPF. This study hypothesizes that inhaled treprostinil will have a positive effect on absolute FVC after 52 weeks of therapy as compared with placebo when administered to subjects with IPF. This is a Phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of subjects with IPF treated with inhaled treprostinil over a 52-week period.Approximately 396 eligible subjects study-wide will be randomly assigned 1:1 to inhaled treprostinil or placebo at Baseline. Randomization will be stratified by IPF background therapy (nintedanib or pirfenidone vs no background therapy). All subjects will initiate inhaled treprostinil (6 mcg/breath) or placebo at a dose of 3 breaths (18 mcg) administered QID (during waking hours) and will titrate to a target dosing regimen of 12 breaths (72 mcg) QID.
More
To evaluate the systemic exposure of treprostinil after inhaled administration in subjects with idiopathic pulmonary fibrosis (IPF)
More
Pulmonary Hypertension
This is a Phase 3, randomized, double-blinded, placebo-controlled study to compare the efficacy and safety of sotatercept versus placebo when added to background pulmonary arterial hypertension (PAH) therapy for the treatment of PAH. The objective of this study is to evaluate the efficacy and safety of sotatercept treatment (plus background PAH therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH. Participants enrolled in the study will have a diagnosis of PAH (Pulmonary Hypertension WHO Group 1) associated with idiopathic/heritable, drug-induced, connective tissue diseases (CTD),or post shunt correction PAH, within WHO FC II or III. Approximately 284 participants will be randomly assigned in a 1:1 ratio to the two study treatment groups (142 participants per arm).
More
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- and high-risk PAH patients.
Participants enrolled in the study will have a diagnosis within 6 months of study screening of symptomatic PAH (WHO Group 1, classified as FC II or III) and presentation of idiopathic or heritable PAH, PAH associated with connective tissue diseases (CTD), drug- or toxin- induced PAH, after shunt correction PAH, or PAH presenting at least 1 year following the correction of congenital heart defects. The objective of this study is to evaluate the effects of sotatercept treatment (plus background PAH therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
More
This is a prospective, non-drug interventional, international, multicenter study to collect real-world data from participants who newly initiate any PAH therapy(ies) in a real-world clinical setting, either as first therapies, as replacement therapies, or as additional therapies.
More
This is a research study involving an investigational drug called PB1046. The word “investigational” means this drug is still being tested in a research setting and is not approved by the U.S. Food and Drug Administration (FDA). Throughout the remainder of this consent form the investigational drug, PB1046 will be referred to as the “study drug”.
The active ingredient in the study drug is a slightly changed form of a protein called vasoactive intestinal peptide (VIP). The VIP protein is normally found in the body. The change made to the natural protein helps to protect the protein from breaking down too quickly. It has been reported in scientific sources that the amount of VIP may be lower in people with Pulmonary Arterial Hypertension (PAH).
This study is being done for multiple reasons. One reason is to see how well participants with PAH tolerate the study drug long term by checking bloodwork periodically and checking for side effects. The study will also see whether your body makes antibodies against the study drug. Antibodies are proteins produced by the body's immune system that are usually found in the blood that help protect our bodies from harm by finding and destroying invaders, like bacteria and viruses. They can also cause harm when they find other proteins that are not normally in the body like the study drug, and these antibodies can make the study drug, or the natural VIP found in our bodies, not work as well or not at all.
More
his study is designed to evaluate the safety and efficacy of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
More
ROR-PH-302 is a 28-week multicenter, randomized, double-blind, placebo-controlled study. Study visits will occur at Day 1 and every 4 weeks through Week 28, with weekly titration phone calls during the first 16 weeks. Approximately 193 subjects with WHO Group 1 PH and on stable background therapy are planned to be enrolled. Subjects who meet entry criteria will be randomly allocated (2:1 ratio) to receive ralinepag or placebo, in addition to their PAH-specific background therapy, as applicable. The primary endpoint is change from Baseline in peak VO2 (assessed by CPET) at Week 28. All subjects who complete the study on study drug through Week 28 will have the option to receive ralinepag in an open-label extension (OLE) study.
More
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. The objective of this study is to evaluate the effects of sotatercept treatment (plus maximum tolerated background PAH therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours, in participants with WHO FC III or FC IV PAH at high risk of mortality. Maximum study duration for a given participant in this study will be up to approximately 49 months as follows:
• Screening Period (up to 4 weeks)
• DBPC Treatment Period (until event occurrence, up to approximately 46 months)
• Follow-up Period (up to 8 weeks)
More
This is a Phase 3, open-label, follow-up study to evaluate the long-term safety and efficacy of sotatercept when added to background PAH therapy for the treatment of PAH. Participants eligible to enroll in the study will have participated in and completed the relevant study requirements of the PAH sotatercept clinical studies. Participants who have discontinued from a previous PAH sotatercept clinical study will not be eligible to enroll in this LTFU study.
More
Study AV-101-002 is a Phase 2b/3 study design where recruitment of subjects will continue as the study progresses from Phase 2b to Phase 3 but the Phase 2b and 3 datasets will be kept separate. The objective of the study is to establish an optimal dose based primarily upon the change in PVR assessed by right heart catheterization (RHC) and the safety and tolerability of AV-101 as evaluated in the Phase 2b Part of the study. The optimal dose will be taken into the Phase 3 Part of the study where the placebo-corrected change in 6MWD after 24 weeks of treatment will be used as the primary endpoint. Except for PVR and 6MWD, all secondary endpoints will be similar across the Phase 2b and Phase 3 Parts of the study including NT-proBNP, multi-component improvement score, WHO Functional Class (FC), clinical worsening, REVEAL Lite 2 risk score, Quality of life (QoL), transthoracic echocardiogram (echo) parameters, and safety and tolerability. All subjects will be given the opportunity to enter into a blinded Follow-up Long-Term extension (LTE) study (IMPAHCT-FUL; Study AV-101-003) on completion of the placebo-controlled parts of Study AV-101 Protocol AV-101-002 FINAL
AV-101-002. Subjects that were on placebo in Phase 2b and entering the LTE study will be re-randomized to one of the 3 active doses until such time as the optimal dose has been selected. Once the optimal dose has been selected, all subjects will be transitioned to the optimal dose while they continue in the LTE.
More
This is a long-term extension (LTE) follow up study where recruitment of subjects will continue as the parent study (AV-101-002) progresses from Phase 2b to Phase 3. Subjects who were on placebo in Phase 2b and the Intermediate Part of the study who enroll in the LTE study will be re-randomized to one of the 3 active AV-101 doses until such time as the optimal dose has been selected. Once the optimal dose of AV-101 has been selected, all subjects will be transitioned to the optimal dose while they continue in the LTE, and subjects completing the Intermediate Part or parent study Phase 3 will enroll into the LTE study at the optimal dose.
More
It is hypothesized that inhaled RT234 will provide a therapeutic benefit for "as needed" (PRN) use in patients with WHO Group 1 Pulmonary Hypertension (PH) (Pulmonary Arterial Hypertension (PAH)) to improve exercise capacity and therefore performance in activities of daily living as well as reduce exertional symptoms (e.g., dyspnea) and their deleterious impacts on quality of life (QoL). The purpose of this study is to demonstrate acute improvements in exercise capacity and exertional symptoms (i.e., dyspnea) post dosing of RT234 as assessed by cardiopulmonary exercise testing (CPET) and 6-minute walk test (6MWT). In addition, acute changes in severity of PAH symptoms before and after CPET and 6MWT will be assessed.
More
This is a Phase 2 study investigating safety and tolerability of Inhaled Treprostinil in participants with Pulmonary Hypertension associated with Interstitial Lung Disease.
More
This is a double-blind, placebo-controlled, randomized Phase 2 study. This study will evaluate the oral inhalation of GB002 in adult subjects with WHO Group 1 PAH who are WHO FC II and III and have a PVR of ≥ 400 dyne•s/cm5. After signing an informed consent form (ICF), subjects will be screened for study eligibility for up to a 5-week screening period. Subjects must continue on stable doses of background PAH medications from 4 weeks before consent and throughout the treatment period. Dose modification of background PAH medications will not be allowed during the screening period. On Day 1 (Baseline visit), eligible subjects will be randomized 1:1 to 1 of 2 treatment groups to receive GB002 twice per day (BID) or placebo. Initially subjects will receive 60 mg BID (4 inhalations BID) for 1 week, after which, subjects will increase the dose to 90 mg BID (6 inhalations BID). Investigational product (IP) dose may be reduced due to tolerability or AEs. Randomization will be stratified by PVR. Subjects will receive IP, BID, over 24 weeks inhaled orally with a dry powder inhaler (DPI). Following initiation of IP in the clinic on Day 1, subjects will return to the clinic every 4 weeks through Week 28 (24 weeks of treatment + 4 weeks of follow-up). Subjects will also be contacted by phone at Week 1 and attend a Week 28 Follow-up visit at the clinic.
More
This double-blind study will compare the efficacy, safety, and tolerability of 2 doses of rodatristat ethyl to placebo in patients with PAH. Eligible patients will be stratified during the randomization process based on the number of background PAH therapies they are receiving (1, 2 or 3) and use of selexipag (yes/no). The number of patients who are receiving a prostanoid infusion will be capped at 50% of the total number of patients enrolled. The number of patients who are receiving selexipag will be capped at 20% of the total enrolled. Patients will be randomized 1:1:1 to placebo, 300 mg BID, or 600 mg BID of rodatristat ethyl. Patients who complete the Main Study will have the option to enroll into the OLE and continue to receive rodatristat ethyl (those randomized to placebo will be re-randomized 1:1 to receive rodatristat ethyl 300 mg BID or 600 mg BID) until the Investigator or patient chooses to stop the investigational product (IP), any stopping criterion in the Main Study is met, IP becomes commercially available, or the Sponsor stops the study for lack of efficacy or a safety signal. Approximately 90 patients with PAH are expected to be enrolled at approximately 45 to 50 study sites in the U.S., Canada, and Rest of World (ROW). This is a parallel group treatment study with 3 arms that is participant, Sponsor, and Investigator blinded. The objective of the OLE is to evaluate the long-term safety, tolerability, and efficacy of rodatristat ethyl in patients with PAH.
More
This is a Phase 3, randomized, double-blind, placebo-controlled dose escalation study to assess the safety and efficacy of pulsed INOpulse versus placebo in study participants with fibrotic interstitial lungdisease (fILD) on oxygen therapy, and thus are considered at risk of having or developing pulmonary hypertension (PH) associated with pulmonary fibrosis (PF).
More
This is a research study to investigate the effectiveness and safety of a device for patients with heart failure with preserved ejection fraction (HFpEF). Patients with a left ventricular ejection fraction greater than or equal to 40%, symptoms of heart failure and elevated filling pressures on a test called a right heart catheterization may be eligible to enroll. Participation in this multicenter study involves being randomly assigned either to implantation of an Inter Atrial Shunt Device (IASD) System II, or a sham procedure. Participants will be followed by the Tufts Heart Failure Research Team at regular intervals, for a total of 5 years; however they will remain under the care of their usual Cardiologist. The IASD System II consists of a self-expanding metal structure that is placed into the wall between the upper chambers of the heart (right and left atria) to enable blood to move between these chambers. For HFpEF patients with high pressures in the left atrium, it is thought that enabling blood to move from the left atrium into the right atrium could improve symptoms such as shortness of breath. This device is not yet approved in the United States. Please look at the study website for more information (www.treatmyheartfailure.com).
More
Multi-center, open-label study for eligible patients who completed Study TDE-HF-301. The primary objective of this study is to evaluate the long-term safety of oral treprostinil in subjects with PH associated with HFpEF for subjects who completed Study TDE-HF-301. The secondary objective of this study is to assess the effect of continued long-term therapy with oral treprostinil on the following:
- 6-Minute Walk Distance (6MWD)
- Borg dyspnea score
- World Health Organization (WHO) Functional Class
- N-Terminal pro-brain natriuretic peptide (NT-proBNP) at Weeks 24 and 48.
More
A multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group study. Approximately 310 subjects will be enrolled and randomly allocated (1:1) to receive oral treprostinil or placebo, stratified by Baseline 6MWD. The primary objective of this study is to assess the effect of oral treprostinil compared with placebo on change in exercise capacity as measured by change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24 in subjects with PH associated with HFpEF. The secondary objective of this study is to assess the effect of oral treprostinil compared with placebo on the following: Change in N-terminal pro-brain natriuretic peptide (NT-proBNP) levels from Baseline to Week 24 Time to clinical worsening where clinical worsening is defined by at least 1
of the following: oospitalization due to a cardiopulmonary indication, Outpatient administration of 1 intravenous (IV) diuretics, Decrease in 6MWD > 15% from Baseline (or too ill to walk) directly related
to disease under study, at 2 consecutive visits on different days, or Death (all causes) Change in World Health Organization (WHO) Functional Class from Baseline to Week 24.
More
Pulmonary Vascular Resistance
Collection of TRV and RVOT VTI from TEE and right heart pressures and CO from PA catheter.
More
Respiratory Infections
We intend to use the measurement of three host-related, serum-based, protein biomarkers using a previously validated score to determine whether a patient with a suspected respiratory illness has a bacterial or viral immune response (or equivocal). These results will then be compared to the decision of the clinical provider to prescribe antibiotics as documented in the patient chart and allow for calculation of potential antibiotic use reduction.
More
The INSURE technique is aimed to reduce ventilation induced lung injury (VILI) but is also associated with repeated doses of surfactant and initiation of CPAP (7). But there is significant variation in peri-extubation practices and approximately 50% of extremely premature infants fail extubation (11). Gupta et al proposed extubation calculator to assess the readiness based on gestational age, age at extubation, pH, FiO2, weight at extubation and peak respiratory severity score in first 6 hours (11). But a major limitation was that the institute did not practice INSURE at that point. Eugenio et al found PROM and GA as predictive factors for successful extubation (12). No studies have so far used pulmonary function parameters to assess extubation readiness
More
Retinal Disorders
1. Men or women ≥18+ years of age with type 1 or 2 diabetes mellitus who have moderately severe to severe Non-proliferative Diabetic Retinopathy 2. Treatment-naïve (ie, no previous anti-VEGF or steroid treatment or PRP or laser within 1,000 μm of the foveal center/treatment for macular edema or DR in the study eye) 3. Willing and able to return for all study visits and comply with study-related procedures
More
Rheumatoid Arthritis
The purpose of the study is to assess whether the addition of a TNFi-biologic (tumor necrosis factor inhibitor) medication to methotrexate (MTX) is superior to adding a targeted synthetic DMARD (disease-modifying anti-rheumatic) medication to MTX for people with active RA despite current MTX treatment.
More
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Rhinitis
Patients suffering from chronic rhinosinusitis (CRS) with polyps (CRSwNP) may be offered pre-operation treatments. While the gross effect of some of these treatments, such as prednisone have been investigated at a gross, cell population level, these studies are generally focused on a subset of the cells found in the tissue, often solely the immune cells. The effect of these treatments on the tissue as a whole, including the underappreciated complexity of the epithelium itself, is a major gap in current knowledge. We are proposing to collect discarded polyp tissue following resection in patients suffering from chronic rhinosinusitis with and without these treatments to determine specific effects these treatments may be having on distinct cell types.
More
Scleroderma
The objective of the trial is to assess the efficacy, safety, and tolerability of BI 685509 compared with placebo on a background of local standard of care (SOC) therapy in the treatment of adult patients with early progressive dcSSc and vasculopathy
More
Sclerosing Cholangitis
This is a 10-year, longitudinal, observational study of patients with PSC to address knowledge gaps in the clinical presentation, natural history, epidemiology, progression, and outcomes of PSC. In addition, the study will address prognostic models and biomarker development. There will be an option to participate in specimen repository at each site for translational studies of genomics and novel biomarkers discovery.
More
Sepsis
The goal of this study is to develop a faster, safer, and more accurate method for determining if a newborn has an infection. This study involves analyzing saliva for markers of infection and inflammation known as cytokines. We will analyze infant’s saliva repeatedly for inflammatory biomarkers within the first 36 hours of their standard of care treatment. We hypothesize that levels of these cytokines will more quickly predict which babies are truly infected and which babies are not compared to the blood test currently being used.
The aims of the study are:
- Aim 1: Develop a predictive model of neonatal infection based pon the expression profile of six salivary inflammatory biomarkers (C-reactive protein/CRP, procalcitonin/PCT, tumor necrosis factor-alpha/TNF-α, interleukin (IL) 1-beta/IL1β, IL6, and IL8, within the first 36 hours of treatment.
- Aim 2: Validate the predictive model of neonatal infection developed in Aim 1 on an external cohort of newborns.
- Aim 3: Establish normative salivary reference ranges of the inflammatory biomarkers across varying gestational ages and weights and assess the potential of these biomarkers to predict other neonatal morbidities.
More
This study is to evaluate Safety & Tolerability of multiple doses of an experimental i.v. medication (called AP-SA02) in Phase 1b and to evaluate Efficacy, Safety & Tolerability of multiple doses of the same experimental medication in Phase 2a, as compared to Placebo in patients with certain bacterial infection (bacteria named Staphylococcus aureus) of your blood stream. The experimental drug or Placebo will be given in addition to any treatment given for the Blood stream infection by Staphylococcus aureus.
More
Shock
Cardiogenic shock (CS) is a dangerous clinical condition where the heart’s ability to pump blood is so compromised that it cannot support the vital functions of the rest of the body. CS has an increased risk of death of 50-60%, and despite tremendous research effort over the last decade, survival outcomes have not changed over this period. Current treatment for CS often involves mechanical circulatory support (MCS) devices, which are mechanical pumps that help support blood flow to the body. These devices primarily support left ventricular (LV) heart function (the function of the main chamber of your heart). However, many patients with CS have right ventricular (RV) dysfunction as well, which is difficult to manage and associated with shortened lifespan. Better recognition and management of right ventricular (RV) failure is therefore critical for improving clinical outcomes in CS. This research will use a new way to measure RV afterload, which is the force resisting the ejection of blood from the RV. We hope that by using this new method, we can better understand how to treat future patients with CS.
More
Sickle Cell Anemia
This is a non-randomized, open label, multi-site, single dose, Phase 3 study in approximately 35 adults and pediatric subjects > 2 and < 50 years of ages with SCD. The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using LentiGlobin BB305 Drug Product, an autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector (LVV) encoding beta A-T87Q-globin gene, suspended in cryopreservation solution in the final immediate container for the intended medical use.
More
Sinusitis
Patients suffering from chronic rhinosinusitis (CRS) with polyps (CRSwNP) may be offered pre-operation treatments. While the gross effect of some of these treatments, such as prednisone have been investigated at a gross, cell population level, these studies are generally focused on a subset of the cells found in the tissue, often solely the immune cells. The effect of these treatments on the tissue as a whole, including the underappreciated complexity of the epithelium itself, is a major gap in current knowledge. We are proposing to collect discarded polyp tissue following resection in patients suffering from chronic rhinosinusitis with and without these treatments to determine specific effects these treatments may be having on distinct cell types.
More
Sjogren's Syndrome
The purpose of this research study is to find out more about the study drug, cenegermin 20mcg/mL ophthalmic solution, in people with severe Sjogren’s dry eye disease. The study will see if cenegermin can safely and effectively relieve the signs and symptoms of this condition, and whether it causes side effects. You will be in this research study for 25 weeks (6 months). If you are eligible to participate in the study, you will be asked to self-administer the study eye drops (cenegermin or placebo) 3 times per day (one drop in both eyes every 6-8 hours) for 4 weeks. Once you have finished 4 weeks of using the study eye drops, you will continue in the study for an additional 20 weeks, so your study doctor can monitor your eyes and health for any side effects. You will be asked to continue your Cyclosporine A eye drops during your study duration, which you were taking prior to enrollment.
You will also be asked to attend the eye clinic for 8 visits. These visits can take up to two hours. At each visit, the study team will ask you about your medical history, symptoms and medications. Your study doctor will also conduct an eye examination. All of the eye examination procedures are considered routine for people with severe Sjogren’s DED.
More
The purpose of this research study is to find out more about the study drug, cenegermin 20mcg/mL ophthalmic solution, in people with severe Sjogren’s dry eye disease. The study will see if cenegermin can safely and effectively relieve the signs and symptoms of this condition, and whether it causes side effects. You will be in this research study for 25 weeks (6 months). If you are eligible to participate in the study, you will be asked to self-administer the study eye drops (cenegermin or placebo) 3 times per day (one drop in both eyes every 6-8 hours) for 4 weeks. Once you have finished 4 weeks of using the study eye drops, you will continue in the study for an additional 20 weeks, so your study doctor can monitor your eyes and health for any side effects.
You will also be asked to attend the eye clinic for 8 visits. These visits can take up to two hours. At each visit, the study team will ask you about your medical history, symptoms and medications. Your study doctor will also conduct an eye examination. All of the eye examination procedures are considered routine for people with severe Sjogren’s DED.
More
Solid Tumors
The purpose of this study is to describe, under real-world conditions, the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
More
Spine Injuries and Disorders
The purpose of this study is to see if the study drug, elezanumab, is safe and able to improve function in patients with acute traumatic cervical spinal cord injury (SCI).
More
Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery.
Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell carcinoma of the head and neck.
More
Staphylococcus aureus
This study is to evaluate Safety & Tolerability of multiple doses of an experimental i.v. medication (called AP-SA02) in Phase 1b and to evaluate Efficacy, Safety & Tolerability of multiple doses of the same experimental medication in Phase 2a, as compared to Placebo in patients with certain bacterial infection (bacteria named Staphylococcus aureus) of your blood stream. The experimental drug or Placebo will be given in addition to any treatment given for the Blood stream infection by Staphylococcus aureus.
More
Status Epilepticus
Status Epilepticus(SE) is a serious condition that needs fast treatment to stop the seizures and prevent permanent brain damage. The purpose of this research is to find out if ganaxolone can stop or decrease the seizure activity in participants who have SE and if ganaxolone is safe compared to placebo when given to participants who are on other anti-seizure medications.
More
Stent Restenosis
A prospective, multi-center, 2:1 randomized (AGENT to POBA), controlled, single-blind, superiority trial. Up to 40 sites in the United States, at least 480 subjects will be enrolled in the trial. An interim analysis will be performed prior to the end of the initial enrollment of 480 patients. The final sample size may be increased up to a maximum of 600 subjects enrolled in the trial.
The objective of this study is to assess the safety and effectiveness of the AgentTM Paclitaxel Coated PTCA Balloon Catheter compared to balloon angioplasty (POBA) in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 26 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.
The AgentTM Paclitaxel Coated balloon catheter is indicated for percutaneous transluminal coronary angioplasty (PTCA) in coronary arteries 2.0 mm to 4.0 mm in diameter and up to 26mm in length, for the purpose of improving myocardial perfusion to treat in-stent restenosis (ISR).
Clinical follow-up: in hospital, 30 days, 6 months, 12 months, then annually through 5 years post index procedure.
The study will be considered complete with regard to the primary endpoint after all subjects have completed the 12-month follow-up period. Subjects who are enrolled but who do not receive a study/ control device will be followed through 12 months only.
More
Strabismus
The aim of our investigation is to determine whether strabismus measurements change significantly after dilation whit cyclopentolate ophthalmic drops in children. The impetus for this study is a recent report published in the American Journal of Ophthalmology, which concluded that in adults, strabismus measurements do not significantly change after dilation with tropicamide and phenylephrine. We would like to replicate this study in a pediatric population with cyclopentolate.
In a hospital or clinical learning institution, there may be multiple clinicians who evaluate a pediatric patient. Because so much of strabismus management is predicated upon the results of cover testing, it is common to ask the attending to repeat the measurement, based on the belief that strabismus measurements can change after dilation. If the results of the aforementioned report were applied to the pediatric population, it could dramatically affect the current standard of care. We want to ensure providers are using the most accurate measurements in their treatment of eye turn.
More
This study aims to determine whether strabismus measurements change significantly after dilation with cyclopentolate ophthalmic drops in children. The impetus for this study is a 2018 report published in the American Journal of Ophthalmology, which concluded that in adults, strabismus measurements do not significantly change after dilation with tropicamide and phenylephrine. We would like to replicate this study in a pediatric population with the standard of care dilating agent: cyclopentolate.
In a hospital or clinical learning institution, there may be multiple clinicians who evaluate the pediatric patient. Because so much of strabismus management is predicated upon the results of cover testing, it is common to ask the attending to repeat the measurement, based on the belief that strabismus measurements can change after dilation. If the results of the aforementioned report were applied to the pediatric population, it could dramatically affect the current standard of care. We want to ensure providers are using the most accurate measurements of their treatment of eye turn.
More
Stress
The goal of this research project is to test the hypothesis that the effects of both positive and negative lifetime experiences of men can be transmitted to their offspring through a specific biochemical change in their sperm, that may also be detectable in their saliva. Thus, we will ask you and your father to fill out a set of short surveys about your positive (resilience building) and negative (early life and adult exposures to severe stress) experiences. We will also ask you to fill out a set of short surveys on your recent mental health, and we will perform biochemical tests on samples of your sperm and saliva. Finally, because there is some evidence that female offspring are affected differently than their male siblings by their father’s experiences, if you have a sister willing to participate, we will ask her to fill out a similar set of short surveys.
More
Stroke
The objective of this study is to compare the safety and effectiveness of the Route 92 Medical Reperfusion System to predicate AXS Vecta Aspiration System.
More
The purpose of this study is to see if the study drug, elezanumab, is safe and able to improve cognitive and/or motor functioning in an individual following the occurrence of acute ischemic stroke. This is a 52-week, Phase 2a, randomized, double-blind, parallel-group, placebo-controlled, multicenter proof-of concept study.
More
The purpose of this research is to enhance and support our understanding and evaluating actual response behaviors of cognitive disability in realistic tasks. We hope to obtain more information about the response behaviors to stimuli during simulated driving of a typical cohort compared to post-stroke cohorts.
More
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE)
More
The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
More
The purpose of this study is to learn if asundexian is safe for the participants, how it affects the body, and to look at how well it works to prevent future ischemic strokes in participants who already had had an acute non-cardioembolic ischemic stroke or high-risk TIA.
More
Abbott developed the AMPLATZER™ PFO Occluder as a minimally invasive, transcatheter PFO closure treatment to further reduce the risk of recurrent stroke among patients with PFO and cryptogenic stroke beyond that achieved with medical management. This additional risk reduction is achieved by blocking the pathway for a venous embolism from reaching the body's arterial system and the brain.
The safety and effectiveness of the AMPLATZER™ PFO Occluder was evaluated in RESPECT, a randomized controlled clinical trial conducted under an investigational device exemption (IDE), which was the largest trial of a transcatheter PFO closure device, with the longest follow-up. RESPECT demonstrated that the AMPLATZER™ PFO Occluder is effective in reducing recurrent ischemic stroke in subjects implanted with the device and can be implanted safely. The AMPLATZER™ PFO Occluder received market approval by FDA on October 28, 2016.
The purpose of this study is the continued evaluation of the long-term safety and effectiveness of the AMPLATZER™ PFO Occluder in a post approval setting.
More
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NIH StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
More
The purpose of this research study is to explore the challenges of recognizing stroke in young adults, the process of making treatment decisions, and the patient’s understanding of the risk of recurrence and long term consequences of stroke. This study consists of a 30 to 60 minute interview of patients with prior stroke (ischemic stroke, transient ischemic attack, or intracerebral hemorrhage) who were 18-50 years of age at the time of stroke onset.
More
This is a single-arm, observational, feasibility study to evaluate if the Halo Alert System can be used in the future to detect stroke events in individuals at risk for stroke wearing the Halo Alert System overnight. The Halo Alert System consists of an EEG sensor headband (Muse-S headband from Interaxon, Inc., Toronto Canada) paired with a data transfer device (Zeit Loop, Zeit Medical, Inc., Redwood City, CA).
More
Structural Heart Disease
Using conductance catheters the study will assess the change in invasively determined cardiac mechanics prior to and following structural heart procedures
More
Aortic stenosis (AS) affects over 12.6 million adults and causes an estimated 102,700 deaths annually. There is interest in novel approaches to identify valve disease earlier the disease course before symptoms occur. We previously used machine learning (ML) to develop a system for fully automated AS screening. Here we are validating the performance of this new method for identifying AS.
More
Subacute thyroiditis
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Subarachnoid Hemorrhage
The primary objective of the study is to determine the optimal intra-arterial drug treatment regimen for arterial lumen restoration after cerebral vasospasm following aneurysmal subarachnoid hemorrhage. The secondary objective is to evaluate clinical outcome 90 days after patient discharge following in-hospital optimal intra-arterial drug treatment for cerebral vasospasm. This study is a prospective multicenter randomized trial.
More
Surgical and Pressure Related Wounds
This is a multisite, randomized controlled clinical trial evaluating the effect of local tranexamic acid on post-operative ecchymosis in eyelid surgery. Patients will act as their own controls with one eyelid receiving a control injection of standard local anesthetic whereas the other eyelid will be randomized to receive a mixture of local anesthetic and tranexamic acid. Post-operative ecchymosis will be graded by a masked reviewer using a validated scale.
More
Surgical Infections
The aim of this study is to assess the anti‐infective efficacy of D‐PLEX administered concomitantly with the Standard of Care (SoC) over a period of 30 days post operation, by preventing surgical site infection (SSI), defined as superficial and/or deep infection in the target incision, compared to the SoC treated control arm, while assessing the safety of D‐PLEX administered concomitantly with the Standard of Care (SoC).
More
Thrombotic Microangiopathy (TMA)
The purpose of this trial is to see if the drug ravulizumab is safe and effective in patients with thrombotic microangiopathy (TMA). This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug. You will recieve the drug or placebo for about 6 months and then have follow-up appoinments for about 6 months.
More
Thyroid Cancer
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Thyroid Nodules
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Transient Ischemic Attack
The purpose of this study is to learn if asundexian is safe for the participants, how it affects the body, and to look at how well it works to prevent future ischemic strokes in participants who already had had an acute non-cardioembolic ischemic stroke or high-risk TIA.
More
Transthyretin Cardiac Amyloidosis
This is an observational study to assess the the burden of neuropathic involvement in wild-type transthyretin amyloidosis
More
Tremor
To evaluate the efficacy and safety of Botulinum Toxin Type A PUrified Neurotoxin Complex (BOTOX) compared to placebo for the treatment of upper limb essential tremor.
More
This is a global, multi-center, noninterventional study that will collect data on patients with PD under standard-of-care treatment according to local routine clinical practice. The primary objective of the study is to assess the impact of the frequency of assessments on the variability over time, reliability, and compliance for the PD diary in patients with PD in whom medications do not provide adequate control of symptoms. The secondary objectives of the study are to document changes in motor function as a measure of disease progression and characterize the stability or rates of change on motor function, quality of life, and use of standard PD medications in patients with PD in whom medications do not provide adequate control of symptoms.
More
Type I Diabetes
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test. The anti TPO levels from blood of patients with Hashimoto thyroiditis or Graves’ disease will be compared with levels from blood of patients with non-autoimmune thyroid diseases (e.g. thyroid cancer) or autoimmune non-thyroid diseases (e.g. Type I diabetes mellitus). This comparison will help to understand how good the Anti-TPO test can aid in the diagnosis of autoimmune thyroid diseases.
Participation in this study will involve one visit and will last approximately 30 minutes. We expect approximately 660 people in the US will participate in the study in the US in accordance with applicable national laws and globally recognized principles. Participation in this study will involve one blood collection for research purposes.
More
Type II Diabetes
The purpose of this clincial trial is to see if the drug CSL346 (developed by CSL Behring) is safe and effective in treating type II diabetic kidney disease. We will look at whether the drug decreases the amount of protein in your urine. The drug is given through the vein and under the skin by research nurses under the supervision of the research doctor. This study is double-blind and placebo-controlled, meaning that neither you nor the study team will know if you are assigned to take the real drug or a saline solution. There is a 50% chance that you will recieve the drug.
More
Urinary Tract Infections
The purpose of the study is to evaluate whether LYS228 can be developed for the treatment of complicated urinary tract infections
More
The purpose of this research study is to determine if IV sulopenem followed by oral sulopenem-etzadroxil/probenecid is safe and at least as effective as standard treatment for urinary tract infections
More
Urine and Urination
Men with severe symptoms of bladder outlet obstruction often have associated bladder fibrosis leading to diminished bladder contractility. Planning to perform a pilot study using 10 urine samples from controls without urinary symptoms and from 10 men with severe urinary symptoms as noted on the International Prostate Symptom Score (IPSS) questionnaire. Assays will determine levels of collagen within the urine samples from both groups.
More
Valvular Heart Disease
The TAVR UNLOAD trial is an international, multi-center, randomized, open-label, clinical trial comparing the safety and efficacy of Transcatheter Aortic Valve Replacement (TAVR) with the SAPIEN 3 Valve and optimized heart failure therapy ( OHFT ) versus OHFT in heart failure (HF) patients, with moderate aortic stenosis ( AS). OHFT is defined as guideline-directed medical therapy. It can be medication only or a combination of medical therapy and approved HF devices.
Clinical efficacy of TAVR is assessed after 1 year of follow-up in all 600 patients. All patients are followed for 2 years to evaluate the value of the study device in to treat patients with Heart Failure (HF) who have moderate aortic stenosis (AS). The Edwards SAPIEN 3 Valve has already been approved by the FDA for use in patients who require an aortic valve replacement due to severe aortic stenosis
More
Vascular Diseases
To determine whether these contributions of the Mineralocorticoid Receptor to vascular function and disease determined in animal models are also implicated in human vessels and to address the impact of sex, age, cardiovascular risk factors, and potentially race, which cannot be completely recapitulated in vitro or in mouse models.
More
Vision Health
This study will evaluate infant vision health based on the history of prenatal drug exposure. Data from this study will be used to create a new process which will include vision health as part of the discharge planning for infants with prenatal drug exposure admitted to Tufts Children’s Hospital
More
Vitamin D Deficiency
A randomized, double-blinded, placebo-controlled, phase III trial (up to maximum n=3000) of early vitamin D3 in vitamin D deficient patients at high risk of ARDS and mortality
More
Vitiligo
The purpose of this study is to continue to assess the effect and safety of ruxolitinib cream on people and their vitiligo with long-term use and also to assess how long the effect lasts on people who stop using ruxolitinib cream.
More
To evaluate the change in immune biomarkers in participants with vitiligo
More
